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Premenopausal women demonstrate preferential accumulation of adiposity in the gynoid 
region, a distribution which shifts towards the abdominal region after the menopausal transition.  
Although estrogen is implicated as a major player in determining body fat distribution the 
mechanisms behind estrogenic action(s) in adipose tissue of women are still unclear.  The global 
aim of this project was to determine if local estrogen influences regional adiposity in 
premenopausal women.  Specifically, we investigated the influence of local estradiol on adipose 
tissue lipolysis as well as estrogen receptor content and adipocyte size in abdominal and gluteal 
subcutaneous adipose tissue of overweight-to-moderately-obese premenopausal women.   
Eighteen overweight-to-moderately obese Caucasian (CA, n=9) and African American 
(AA, n=9) women were recruited. Between 15 and 17 of these women took part in each of the 
 
  
three studies.  We found the influence of estradiol on lipolysis to be adipose tissue depot specific 
and treatment dependent, with estradiol perfusion blunting the response to lipolytic stimulation 
under some conditions while potentiating this response in others.  Furthermore, we found 
differences in abdominal and gluteal estrogen receptor alpha (ERα) and estrogen receptor beta 
(ERβ) protein content, potentially revealing region specific actions of estrogen through these 
estrogen receptors in adipose tissue.  Finally, we found racial differences in adipose tissue 
morphology, as indicated by variations in adipocyte diameter populations in CA and AA women 
(higher proportion of medium size adipocytes in abdominal and gluteal subcutaneous adipose 
tissue of CA and higher proportion of small adipocytes in gluteal region of AA) which could 
underlie the increased chronic disease risk in AA compared to CA women for a given body mass 
index (BMI).   
Our findings indicate depot specific influence of estradiol on lipid mobilization may play 
a role in the predominant gluteal-femoral body fat distribution of premenopausal women.  It is 
possible that depot specific effects of estradiol may be a result of regional differences in estrogen 
receptor content.  Racial divergence in adipocyte morphology is an adipose tissue characteristic 
potentially underlying differing disease risk between CA and AA women of similar BMI.  The 
integration of these results provides insight towards a more complete understanding of regional 
adiposity in overweight-to-obese premenopausal women, but future studies must be conducted to 
uncover the interaction between estrogen receptor content and local estrogen action as well as the 
direct physiological consequences of these findings. 
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CHAPTER 1: Review of Literature 
 
Obesity, Body Fat Distribution, and Disease Risk 
Excess weight increases the risk of multiple disease states, including heart disease, 
hypertension, Type 2 diabetes, certain cancers (e.g. colon and breast) and stroke (1-4).  The 
associations between adiposity and the Metabolic Syndrome and cardiovascular disease (CVD) 
are believed to follow a region-specific scale such that abdominal visceral adiposity predicts the 
highest risk, abdominal subcutaneous adiposity predicts an intermediate risk that is independent 
of the visceral depot, and femoral adiposity may actually predict metabolic protection (5, 6).   
The idea that localization of body fat, and not merely total fat mass, holds high 
importance in the elevated health risks associated with obesity is not a new idea.  Awareness of 
regional fat patterning has been demonstrated from the earliest recorded works of humankind.  
The development of systematic methodology for categorizing human body shape was pioneered 
in the 1930s (7).  In 1947 J. Vague first suggested that the relative amount of upper- versus 
lower-body obesity was important (8) and could be quantified by an average of two ratios, 
contrasting the fat at the nape of the neck with that at the sacrum, and the ratio of fat-to-muscle 
area in the arm with that in the thigh (9).  He further hypothesized that, although the gynoid (or 
lower-body) obesity typically seen in women is benign, android (or upper-body) obesity is 
 2 
 
common among individuals with such health problems as diabetes, gout, and atherosclerosis.  
Evidence from more recent body composition studies suggests adipose tissue distributed in the 
intra-abdominal or visceral region (also known as “android”, central, or male-pattern body fat 
distribution) carries a much greater risk for metabolic and cardiovascular disorders than does 
adipose tissue distributed subcutaneously (7, 10-13).  There is also evidence that lower-body 
adiposity is actually protective against disease risk, rather than simply less harmful (5, 14-19).   
Although central visceral and abdominal subcutaneous adipose tissue distribution is more 
closely associated with increased metabolic and CVD risk, research conducted on adipose tissue 
should not be limited to understanding fat deposition in these depots alone.  Uncovering the 
physiology behind how and why premenopausal females preferentially carry adiposity 
peripherally, possibly protecting them from obesity associated diseases may help in development 
of abdominal obesity prevention strategies for women, particularly after menopause. 
 
Racial Differences in Obesity and Disease Risk 
According to data from the National Health and Nutrition Examination Study (NHANES) 
results from 2009-2010 the prevalence of age-adjusted obesity (Body Mass Index [BMI] ≥ 30 
kg/m
2) and obesity and overweight (BMI ≥ 25 kg/m2) in women at least 20 years of age or older 
in the United States is 35.8% and 63.7% respectively, with the mean age adjusted BMI for 
women being 28.7 kg/m
2
 (20).  African American women tend to be more obese than Caucasian 
women (20, 21), with obesity prevalence in non-Hispanic white women being 32.2% while in 
non-Hispanic black women it is 58.5% (20).   
Caucasian (CA) and African American (AA) women are reported to have different body 
fat distributions for a given amount of total body adiposity.  AA, in comparison to CA, women 
 3 
 
have less visceral adipose tissue (VAT) for a similar age and BMI (22-24), and/or have greater 
amounts of subcutaneous adipose tissue (SAT) even after adjustment for total body fat (23, 25, 
26).  Visceral adipose is most commonly the depot implicated in elevated disease risk, yet AA 
women have more cardiovascular disease risk factors (e.g. increased BMI) (27) and a higher 
incidence of Type 2 diabetes mellitus (T2DM) and hypertension than CA women (28) despite 
preferential accumulation of adiposity in SAT.  In fact, the relationship between central fat 
deposition and metabolic risk factors is weaker in African Americans in comparison to 
Caucasians (23).  This evidence supports an important pathophysiological role for accumulation 
of adiposity even within the “less dangerous” subcutaneous depot. 
The importance of the abdominal SAT depot contributing to disease risk is a point of 
particular significance in overweight and obese African American women, particularly in regards 
to risk of insulin resistance (29, 30).  Decreased insulin sensitivity in black women is most 
closely associated with the increased abdominal SAT while in white women this association was 
equal between VAT and SAT (31, 32).  The preferential accumulation of subcutaneous adiposity 
in AA women as well as the divergent association between subcutaneous adiposity and disease 
risk between CA and AA women potentially indicates an inherent difference in SAT 
characteristics between these groups, a topic requiring future investigation.   
 
Regional Adiposity Association with Circulating Sex Hormones 
The distribution of adipose tissue is divergent by sex.  Men have a more central 
(abdominal) accumulation of fat, whereas women have more peripheral (gynoid, gluteal/femoral) 
accumulation (33-35).  Men also have a higher incidence of CVD than women, until menopause 
when the incidence of CVD and central adiposity increases in women (36).  This 
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epidemiological and clinical evidence suggests a large role for sex hormones in the regulation of 
adipose tissue distribution and disease risk (37). 
Strong evidence from multiple large randomized controlled trials has accumulated to 
demonstrate that postmenopausal women on hormone therapy (HT) gain less weight than women 
on placebo (38-41).  In the Heart Estrogen/progestin Replacement Study (HERS) (39) and the 
Women’s Health Initiative Estrogen + Progesterone (WHI E+P) trial (41), women on HT lost 
significantly more weight than placebo-treated controls.  In two other trials (38, 40) women on 
HT gained roughly 40% less weight than women on placebo.  In the single trial (38) that 
included an E-only treatment arm, the attenuation of weight gain tended to be more effective 
with E-only (although not significant) than with E+P therapy, strongly suggesting that the 
mechanism for the attenuation of weight gain is estrogen mediated.  Several smaller physiologic 
studies also found an attenuation of weight gain by HT, although not all differences were 
statistically significant (42-47).  Importantly, although the large trials did not measure body 
composition, the smaller studies provide evidence that attenuation of weight gain by HT reflects 
a significant attenuation of fat gain, primarily in the trunk region (40, 42, 47) since leg fat mass 
either did not change (45) or increased (47) in response to hormone treatment. 
If sufficient circulating estradiol (E2) attenuates weight gain in postmenopausal women, it 
would be expected that suppressing circulating E2 in young women would promote weight gain.  
In fact, evidence that this occurs comes from studies of premenopausal women on gonadotropin 
releasing hormone agonist (GnRHAG) therapy to suppress sex hormone levels (48-52).  Fat mass 
increases significantly in response to 4 to 6 months of GnRHAG therapy (48, 49, 52) and non-
significantly in response to 3 months of therapy (50, 51).  Specifically, 4 months of GnRHAG 
therapy has been shown to significantly increase trunk (7.5% to 10%) but not leg (<2%) fat mass 
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(49, 52).  Collectively this evidence supports the hypothesis that the loss of circulating sex 
hormones, particularly estrogen, leads to a depot specific (abdominal versus gynoid) change in 
adiposity supporting the preferential accumulation of abdominal adipose tissue, however the 
mechanism behind this change remains unknown.   
 
The Lipolytic Cascade 
 
Figure 1.1. The lipolytic cascade.  In the non-activated (i.e. un-stimulated) state, HSL is dispersed in the cytoplasm 
and perilipin coats the lipid droplets while binding CGI-58.  ATGL is cytosolic and partly bound to the lipid droplet.  
Stimulation of lipolysis by catecholamines through adenylyl cyclase, or natriuretic peptides through guanylyl 
cyclase, increases intracellular cAMP and cGMP levels, in turn activating PKA and PKG, both leading to the 
phosphorylation of perilipin and HSL.  HSL phosphorylation leads to its translocation from the cytosol to the 
surface of the lipid droplet.  CGI-58 disassociates from phosphorylated perilipin into the cytosol where it can then 
bind to and activate ATGL to hydrolyze TAG leading to DAG production.  HSL and MGL contribute to the final 
hydrolysis of DAG and MAG.  Concomitant enhancement of ATGL, HSL and MGL activities is necessary for full 
hydrolysis of TAG and release of NEFAs and glycerol.  Docking of FABP4 to HSL favors the outflow of NEFAs 
from the cell.  Adapted from (53).  ATGL, adipose triglyceride lipase; ATP, adenosine triphosphate; cAMP, cyclic 
adenosine monophosphate; cGMP, cyclic guanosine monophosphate; CGI-58, Comparative gene identification-58; 
FABP4, Fatty acid binding protein 4; HSL, hormone-sensitive lipase; MGL, monoacylglycerol lipase; NEFA, non-
esterified fatty acid; PKA, protein kinase A; PKG, protein kinase G; (P), phosphorylation site in phosphorylated 
perilipin and phosphorylated HSL; TAG, triacylglycerol; DAG, diacylglycerol; MAG, monoacylglycerol. 
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Adipose tissue is the human body’s largest energy storage compartment, with most 
energy reserves being stored in fat cells as triacylglycerols (TAG).  Regulation of storage and 
mobilization of TAG in adipocytes is important in regional fat accumulation (54), as an 
imbalance between the hydrolysis and synthesis of TAG can play a substantial role in the 
development and maintenance of obesity.  The capacity of adipose tissue to buffer plasma TAG 
concentrations by increasing plasma TAG clearance through the activity of lipoprotein lipase 
(LPL) as well as suppressing the release of non-esterified fatty acids (NEFA) by decreased 
lipolysis, is of primary importance in maintaining cardiovascular and metabolic health (55).  For 
example, it is typical for individuals with upper body obesity to experience excessive NEFA 
release along with impairments in NEFA utilization by liver and skeletal muscle, leading to 
metabolic abnormalities and increased risk of Type 2 diabetes (53). 
Lipolysis is the catabolic process by which stored TAGs are broken down into NEFAs 
and glycerol (Figure 1.1).  It has not been fully established what sets the inherent rate of adipose 
tissue lipolysis in the human body.  Catecholamines, insulin, and adenosine are recognized as the 
major lipolytic regulators in humans, but it is likely that many other factors are also involved.  
There are three main lipases involved in hydrolysis of intracellular TAGs: 1) adipose triglyceride 
lipase (ATGL), 2) hormone sensitive lipase (HSL), and 3) monoacylglycerol lipase (MGL).  
Each TAG is hydrolyzed into three NEFAs and one glycerol.  The NEFAs are either re-esterified 
into new TAG within the adipose tissue or efflux from the adipocyte and are transported in the 
blood to other organs for metabolism.  Glycerol is primarily transported to the liver; the lack of 
the enzyme glycerol kinase does not allow for the adipocyte to utilize the glycerol produced 
through lipolysis (53). 
 7 
 
The lipolytic cascade is activated or inhibited by regulators of lipolysis through their 
binding to plasma membrane receptors on the adipocyte.  Multiple adipocyte cell surface 
receptors have a regulatory role on lipolysis (i.e. adrenergic receptors, adenosine receptors, etc.), 
most of which are coupled to adenylyl cyclase or guanylyl cyclase, and in turn stimulate 
lipolysis, by the stimulatory G-protein complex (Gs).  However, some receptors, such as the 
alpha-2 adrenergic receptors (α2-AR) are coupled to the lipolytic enzymes by the inhibitory G-
protein  complex (Gi) and thereby inhibit lipolysis.  The stimulation of adenylyl cyclase leads to 
an increase in 3'-5'-cyclic adenosine monophosphate (cAMP) (or cyclic guanosine 
monophosphate [cGMP] in the case of guanylyl cyclase) which in turn promotes activation of 
cAMP dependent protein kinase A (PKA) (or cGMP dependent protein kinase G [PKG]) 
promoting the progression of the lipolytic cascade.  Just the opposite is true when the Gi complex 
is activated, which results in a decrease in cAMP/cGMP and inactivation of PKA/PKG, turning 
off progression of the lipolytic cascade (Figure 1.1) (56). 
 
Modulation of Lipolysis 
 Regulation of lipolysis is a multifaceted process through which a large portion of the 
maintenance of fuel homeostasis in the human body takes place.  Several hormonal and non-
hormonal factors participate in the regulation of lipolysis in a complex and balanced system.  
Throughout a given day this system is under constant demand from the ever changing needs of 
lipid utilizing tissues, with times of rest, exercise, feeding, and fasting creating unending 
physiological situations requiring the response of the lipolytic cascade to meet new demands.      
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Stimulation of Lipolysis 
 Catecholamines are the primary hormones involved in stimulating lipolysis in humans.  
Catecholamine exposure to the adipose tissue occurs through general circulation and local blood 
flow (epinephrine, norepinephrine) (57) or through sympathetic innervation of the adipose tissue 
(norepinephrine) (58).  Catecholamines stimulate lipolysis through beta-adrenergic receptors (β-
AR), of which there are three subtypes (β1-AR, β2-AR, and β3-AR) present and active in human 
adipose tissue (59); however, in healthy subjects catecholamine induced lipolysis in adipose 
tissue is believed to be predominantly mediated by β2-ARs (60).  Visceral adipose tissue 
expresses β3-ARs and it is in this depot where this β-AR subtype most likely has its greatest 
effects, playing only a minor role if any in subcutaneous adipose tissue (57). 
 Other known stimulators of lipolysis are atrial natriuretic peptide (ANP), glucocorticoids, 
thyroid hormones (61, 62), growth hormone (63, 64), sex steroid hormones (15, 37, 65), and 
tumor necrosis factor-alpha (TNF-α) (66, 67), but these factors will not be discussed further in 
this review. 
 
Inhibition of Lipolysis 
 The balance between expression of pro-lipolytic β-ARs and the anti-lipolytic α-ARs 
within adipose tissue determines the net effect of catecholamines on lipolysis.  Most studies of 
human adipose tissue conclude that the stimulatory effects of β-ARs predominate over the anti-
lipolytic role of α2-ARs in times when fat mobilization is necessary (68).  However, in situ 
microdialysis studies have revealed an anti-lipolytic role for α2-ARs during resting conditions, 
potentially helping to maintain low tonic levels of lipolysis (69).  
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Adenosine and insulin are the other two predominant regulatory factors demonstrating an 
anti-lipolytic effect (53, 56, 70-72), but insulin-like growth factor-1(IGF-1) (73), prostaglandins, 
neuropeptide Y (74-76), and nitric oxide (NO) also most likely have a role in decreasing lipolysis 
(77). 
 
Pharmacological Modulators of Lipolysis 
 Investigations of lipolysis are commonly conducted in vitro either in primary adipocyte 
cell culture or isolated adipocytes from human adipose tissue biopsy samples.  In vivo 
investigations of lipolysis can be conducted by measurement of systemic lipolytic rates or study 
of individual tissue depots (78).  Local pharmacological or physiologic effects of drugs or 
hormones can be investigated via the microdialysis technique, through which measured changes 
in interstitial glycerol concentrations are an indicator of alterations in local lipolytic rate.  In vitro 
incubations or microdialysis perfusion with pharmacological agents allows for controlled 
alterations in the local environment serving to stimulate or antagonize lipolysis.  Adrenergic 
receptor targeted pharmacological agents such as isoproterenol and phentolamine are two of the 
most commonly used agents to specifically alter lipolytic rate through distinct adrenergic 
mediated mechanisms.  The use of these targeted agents allows for determination of the relative 
contribution of the specific adrenergic receptor subtypes within the fat cells (69, 79)  
Isoproterenol is a non-specific β-AR agonist which leads to Gs stimulation of adenylyl cyclase 
and in turn increases signaling through the lipolytic cascade.  On the other hand, phentolamine is 
a non-specific α-AR antagonist which binds to the α-AR receptors, in turn inhibiting the binding 
of catecholamines to these receptors and ultimately relieving inhibition of lipolysis that would 
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take place through activation of the α-AR receptor.  Perfusion of each of these pharmacological 
agents is known to increase lipolysis as measured by microdialysis (69, 80).   
 
Racial Differences in Lipolysis 
 Racial differences in lipolytic rate are evident but conflicting evidence exists.  In a study 
by Albu et al. systemic lipolysis as measured by whole body glycerol turnover (rate of 
appearance) was lower in premenopausal obese black women than obese white women both at 
rest and in response to insulin suppression (pancreatic euglycemic clamp), with VAT 
accumulation being highly associated with the systemic resistance to the antilipolytic effect of 
insulin (81).  A lower HSL mass and significantly lower basal lipolytic rate in both the SAT and 
VAT of AA compared with CA women was also reported by Barakat et al. (82),  in further 
support of the belief that AA women have a lower basal lipolytic rate compared to CA women.   
Conversely, adipocytes from postmenopausal AA exhibited a higher basal lipolytic rate 
and decreased insulin responsiveness in in vitro experiments conducted by Fried et al. (83).  This 
decreased insulin responsiveness was highly related to the participants hyperinsulinemia.  Two 
additional studies also found higher rates of lipolysis in black compared to white women from 
South Africa.  The first found higher interstitial glycerol via in situ microdialysis (abdominal and 
femoral SAT) in the postabsorptive state and after an oral glucose tolerance test in black women 
(84) and the second found higher circulating fatty acids and decreased responsiveness to the 
antilipolytic effect of insulin in adipocytes isolated from the abdominal and femoral depots of the 
same women (85).  Differences between in vivo and in vitro techniques in measurements of 
lipolysis as well as variations in participant populations may have led to the conflicting results in 
regards to black women demonstrating a lower basal lipolytic rate compared to white women.  
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Increased total numbers of β-ARs have been found in both the SAT and VAT from 
middle aged obese AA versus CA women signifying a higher potential for lipolysis (86).  
Barakat et al. found AA women demonstrated an increased lipolytic response to isoproterenol 
compared to CA women, despite having a lower basal lipolytic rate and HSL mass (82).  An 
increased efficiency of the HSL signaling pathway was hypothesized to be the explanation 
behind the increased lipolytic response to isoproterenol even with a decreased HSL mass (82).  
Accordingly, it could be hypothesized that AA women would demonstrate an increased lipolytic 
response to submaximal exercise stimulation.  However, there is a paucity of research 
investigating racial differences in exercise stimulated lipolysis in women and therefore evidence 
is lacking to support this hypothesis. 
Although a full understanding is lacking, it seems clear that there is a divergence in both 
basal lipolytic rate and response to lipolytic stimulation in SAT of CA and AA women.  This 
racial difference in lipolysis may play a role in preferential adipose accumulation in SAT 
compared to VAT in AA compared to CA women.     
 
Regional Differences in Lipolysis 
Evidence suggests that gluteal-femoral adipose tissue may actually be a fat sequestering 
storage depot in females.  Femoral adipocytes, compared with abdominal adipocytes, have 
increased expression of α2-ARs as well as increased insulin sensitivity (87-89), promoting 
storage of TAG and inhibiting lipolysis in that region.  Further, in vivo measures of basal free 
fatty acid release (lipolysis) indicate a lower lipolytic rate in the lower body compared with the 
upper body adipose tissue (90).  However, investigations of regional differences in basal 
lipolysis (represented by interstitial glycerol) measured by the in situ microdialysis technique 
 12 
 
have detected greater dialysate glycerol concentrations in the femoral versus abdominal SAT 
(91, 92). These unexpected findings of higher dialysate glycerol concentration from femoral 
adipose tissue may be explained by an increased adipocyte cell size in this region (93, 94) as 
rates of lipolysis are known to be directly related to fat cell size (95-98).  It is possible that the 
lower response to lipolytic stimulation in the gluteal-femoral compared to abdominal SAT, and 
not basal differences, are primarily responsible for the characteristic fat sequestration of the 
lower body depots. 
Regional differences in lipolytic activity may be a mechanism by which premenopausal 
women maintain their gynoid fat distribution.  It is possible that the preference for adipose 
storage in the gynoid region in premenopausal women serves a specialized function, being an 
important source of energy supply during pregnancy and lactation (94, 99, 100).  
 
Adipose Tissue Blood Flow 
 The importance of the microcirculation of adipose tissue is paramount in the regulation 
and function of adipose tissue metabolism and the maintenance of human health.  The local 
blood flow is responsible for transporting hormones and other factors from the circulation to the 
adipose tissue, as well as allowing clearance of metabolites from the adipose tissue into the 
circulation.  Adipose tissue blood flow (ATBF) is regulated by a multifaceted system which is 
highly responsive to metabolic conditions such as fasting, feeding, and exercise.  In the fasted 
state blood flow through the adipose tissue is greater than that through resting skeletal muscle 
(101).  During prolonged fasting or exercise ATBF is increased in order to supply albumin 
needed for the transport of released NEFA into circulation, and after feeding ATBF increases to 
enhance substrate delivery for TG clearance  (101).  Exercise can result in increased ATBF even 
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in adipose tissue that is distant from the working skeletal muscle (102).  Blood flow is directly 
affected by local concentrations of substrates and hormones involved in lipid metabolism (103), 
as well as both β-AR (vasodilation) (104-106) and α2-ARs (vasoconstriction) (105, 107), 
sympathetic innervation of the vasculature as well as adipocytes (101, 108), endothelial nitric 
oxide (105), ANP (109, 110), and potentially many other factors.   
It is clear that the rate of adipose tissue blood flow is not the same in all depots.  
Specifically, blood flow in the gluteal-femoral region is much lower than in the abdominal 
adipose tissue (111).  Initially the lower blood flow in this region was attributed to the inert 
qualities of the lower body SAT; however, there are likely other mechanisms responsible, as this 
adipose tissue depot is still quite metabolically active and involved in metabolic homeostasis. 
  
Sources of Estrogen in Women 
Adipose tissue acts as a metabolic sink with the ability to take up estrogen from the 
circulation, but the circulating concentration is not the sole determinant of adipose tissue 
exposure to estrogen.  Although the ovaries are the principal source of systemic estrogen in 
premenopausal women, other sites of estrogen biosynthesis are present throughout the body.  
These extragonadal sites such as the mesenchymal cells of the adipose tissue and skin, 
osteoblasts in bone, vascular endothelial and aortic smooth muscle cells, and a number of sites in 
the brain are sources of estrogen in both men and women (112).  In fact, adipose tissue becomes 
the major source of estrogen production in postmenopausal women (113).   
The estrogen synthesized within these extragonadal compartments is primarily active at 
the local tissue level in a paracrine or intracrine fashion (113), only entering the circulation if it 
escapes local metabolism (114).  Accordingly, the total amount of estrogen synthesized by 
 14 
 
extragonadal sites may be small, but the local tissue concentrations achieved are probably high 
and likely exert significant local biological influence (113). Thus, these sources of estrogen may 
play an important, but largely unrecognized, physiological and/or pathophysiological role within 
the adipose tissue (114). 
The conversion of inactive precursor C19 steroids to produce active androgens and 
estrogens in human peripheral tissues is a process that depends on the expression of 
steroidogenic enzymes in the tissue, particularly aromatase (P450arom) (114) and 17β-
hydroxysteroid dehydrogenase (17β-HSD) (115).  The enzyme aromatase expressed in human 
adipose tissue is responsible for the conversion of testosterone to E2 as well as androstenedione 
to estrone (E1).  Human adipose tissue also possesses the 17β-HSD enzyme which is responsible 
for the conversion of the weak estrogen E1 to the more biologically active estrogen E2 and 
androstenedione to the potent androgen testosterone (115).   
Depot specific steroidogenic enzyme expression and activity allows for local regulation 
of the amounts of active steroids in the adipose tissue on a cellular basis (116) and may 
contribute to regulation of adipocyte metabolism at the local level (115).  Importantly, aromatase 
enzyme activity differs between adipose tissue depots, with higher activity in the thigh, buttock 
and flank versus abdominal fat (113, 117) and higher in subcutaneous versus visceral 
preadipocytes (118) of premenopausal women.  Therefore, fat depot-specific differences in 
intracrine conversion of testosterone to estradiol (i.e. aromatase activity) may play a role in 
mechanisms underlying region specific patterns of fat distribution (116, 118). 
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Estrogen Receptor Expression in Human Adipose Tissue 
The estrogen receptor (ER) was first detected in human adipose tissue in 1993 (119).  In 
1998 multiple ER subtypes (ERα and ERβ) in human adipose tissue were first identified (120).  
Since then many studies have confirmed that ERα and ERβ mRNA and protein are expressed in 
human adipose tissue (121-125).  Most recently mRNA for the G protein-coupled Estrogen 
Receptor (GPER) has also been detected in omental and subcutaneous abdominal adipose tissue 
of humans (126). 
Expression of ERα (mRNA and protein) in adipocytes from normal weight men and 
women does not appear to be different between subcutaneous and visceral depots in either sex 
(123), but evidence for lower ERβ expression in VAT does exist (121).  ERβ mRNA expression 
appears to be lower compared to ERα mRNA (123) in measurements from mature human 
adipocytes in both men and women, potentially indicating that ERα is the primary receptor 
responsible for estrogen action within adipose tissue.  However, the importance of ERβ within 
adipose tissue cannot be dismissed due to lower expression.  Support for a role of ERβ within 
adipose tissue is evident in studies conducted in ER knockout models (127).  Potentially, it is the 
ratio of ERα-to-ERβ expression that may be the determining factor in the specific role of 
estrogen on adipose tissue metabolism within a given adipose tissue depot. 
Interestingly, exposure to E2 can alter ER expression itself.  Anwar et al. demonstrated 
that chronic E2 treatment lead to an up-regulation of both ERα and ERβ in stromal cells from 
SAT and VAT of healthy older women, but decreased ERα expression and increased ERβ in 
adipocytes from SAT (122).  In VAT adipocytes E2 exposure led to an increase in ERα 
expression (122).  Because adipose tissue is a sink for estrogen storage as well as a producer of 
estrogen itself, it is possible that local concentrations of estradiol play a role in ER expression, 
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potentially in a region specific manner.  It is not known if there is a relationship between regional 
adipose tissue estradiol concentration and ER expression in humans in vivo. 
 
Regional Differences in ERα and ERβ Expression 
Only one study has investigated regional differences in ER expression in peripheral 
adipose tissue depots, reporting only mRNA expression.  Pedersen et al. found no difference in 
ERα mRNA expression between abdominal and gluteal SAT, but did find ERβ isoforms ERβ-4 
and ERβ-5 to be significantly higher in the gluteal versus abdominal SAT in the same women 
(121).  There are a paucity of studies investigating the expression of GPER in abdominal and 
gluteal SAT, but Hugo et al. did find 1.4 fold higher GPER mRNA expression from abdominal 
SAT compared to VAT of obese individuals (126). 
 
Obesity and ER Expression 
In premenopausal women obesity is associated with lower ERα mRNA levels compared 
to those of normal weight, and weight loss via caloric restriction results in increased ERα 
expression (128, 129).  These alterations in ERα expression with obesity and weight loss indicate 
an association between ERα and lipid metabolism.  Whether reduced ERα mRNA is a cause or 
consequence of obesity in women cannot be established from these previous investigations; 
therefore, more research is needed to understand the role of ER expression in obesity in women. 
Further investigation into the role of estrogen receptors in adiposity comes from a study 
done in ovariectomized (OVX) female mice treated with vehicle, E2, propylpyrazoletriol (PPT; 
an ERα agonist), and diarylpropionitrile (DPN; an ERβ agonist).  Vehicle or DPN treatment in 
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OVX mice lead to an increase in body weight, whereas treatment with E2 or PPT decreased body 
weight (130), supporting the role for ERα in the maintenance of adipose accumulation. 
 
Evidence from ER Knockout Models for Direct ER Modulation of Adiposity 
The development of transgenic mice in which ERα (131) and/or ERβ (132) have been 
knocked out allow investigation of the specific role of each receptor in various tissues throughout 
the body.  Female ERα knockout (αERKO) mice demonstrate a marked increase in white adipose 
tissue, insulin resistance, and impaired glucose tolerance compared to wild type (133), 
implicating the E2/ERα signaling pathway in regulation of female white adipose tissue 
deposition.  In particular it seems that ERα, at least in the female mouse model, plays a critical 
inhibitory role in the development and total amount of white adipose (133).  However, these 
changes in αERKO mice might not be a product solely of the lack of ERα, but also due to the 
resultant shift in ERα/ERβ ratio or other the actions of estrogen receptors such as GPER.  
αERKO mice also demonstrate increased circulating E2 levels, potentially exaggerating the 
signaling and resultant actions of estrogen through other ERs in adipose tissue.  Upon 
ovariectomy, αERKO mice (effectively void of E2/ERβ signaling) demonstrate a reduction in 
body weight, fat pad weight and adipocyte size, and a normalization of circulating glucose and 
insulin, suggesting ERβ is a mediator of these negative adipose and glucoregulatory effects and 
confirming that both forms of ER have a role in estrogen effects in adipose tissue (127).   
Female ERβ knockout (βERKO) mice do not demonstrate the obesity characteristics of 
ERα knockout models while double ERα/ERβ knockout (DERKO) models express similar 
increases in body fat content to αERKO (134).  After ovariectomy, gonadal fat mass is reduced 
by estrogen treatment in wild type and βERKO but not αERKO or DERKO, again demonstrating 
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that ERα is responsible for this regulation of fat mass (133, 135, 136).  An increased estrogenic 
response is also demonstrated in βERKO mice, indicating that ERβ may act as a repressor of the 
ERα mediated effects (135).  
 
Opposing Effects of ERα and ERβ 
 ERβ has been reported to inhibit the transcriptional activity of ERα possibly through 
ERα/ERβ heterodimer formation (137), indicating the importance of the ratio of ERα-to-ERβ in 
the biological response to estrogens (123).  Furthermore, differing tissue specific expression as 
well as varying phenotypes between ERα and ERβ knockout models confirm that each ERα and 
ERβ are responsible for different biological functions (133, 136).  The relative expression of 
ERα and ERβ determine cellular sensitivity to estrogens (137) and although ERα is thought to be 
the more dominant of the two receptors, co-expression of ERβ results in decrements in estrogen 
stimulated responses (137).  This evidence emphasizes the importance of determining the co-
localization of these two receptors in defining the actions of estrogens in specific target tissues 
(137).   
 
G protein-coupled estrogen receptor (GPER) 
Very little is known about GPER, particularly within adipose tissue.  GPER was first 
identified in the late 1990s by multiple groups (138, 139) and GPER deficient models have 
confirmed its role as an ER in vivo (140, 141).  GPER mRNA has been detected in human 
abdominal SAT, VAT, and breast tissue from obese women (126), but to our knowledge the 
former is the only study to date to investigate GPER expression in human adipose tissue.  
Although controversial (140), GEPR deficiency has been associated with abdominal obesity in 
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both male and female animals (141).  Together, GPER expression in human adipose tissue and 
its association with an obese phenotype in GPER deficient mice makes it a promising candidate 
for mediating at least some of the direct effects of estrogen within human adipose tissue.   
 
Mechanisms of Estrogen Action in Adipose Tissue 
The exact mechanism for sex steroid action within adipose tissue and subsequent 
regulation of regional adiposity is unknown.  As discussed previously, estrogen can be taken up 
from the circulation into adipose tissue or produced within adipose tissue.  Regardless of the 
origin of the local estrogen, there are two main regulatory actions it can have within the adipose 
tissue: 1) regulation of key proteins at the genomic level by transcriptional means and 2) acting 
on secondary messengers at the cell membrane by non-genomic effects.  The presence of sex 
steroid receptors in the nucleus and cytosol of the adipocyte as well as on the plasma membrane 
prove the cellular machinery for both genomic and non-genomic mechanisms of action are 
present within adipose tissue.  It is most likely a combination of these two pathways ultimately 
resulting in the many regulatory actions of sex steroids within adipose tissue.   
The classical mechanism of action of sex steroid hormones involves the following 
cascade of events: 1) the steroid enters the target cell and 2) binds with high affinity to a specific 
receptor, 3) the steroid-receptor complex undergoes a conformation change and 4) is then able to 
bind to a specific DNA response element, 5) resulting in up- or down-regulation of the 
transcription of a given gene (37).   
 Although transcriptional regulation by sex steroid hormones has been the most highly 
studied mechanism of action, non-genomic mechanisms of sex steroid action within target 
tissues are also evident (142).  Non-genomic actions are typically rapid, occurring in minutes, 
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whereas transcriptional regulation takes place on a slower timeline; over hours to days (143, 
144).  The mechanism of action in the non-genomic sequence of events involves a steroid 
receptor on the plasma membrane with a second messenger inside the cell to carry out the action 
of the steroid.  Anwar et al. identified both ERα and ERβ in cellular membrane of abdominal 
SAT as well as omental human adipose tissue (122).  Although the membrane associated ERα 
and ERβ are reportedly associated with caveolar endocytic vesicles, much remains to be 
determined about the exact mechanism of action of steroid hormones by membrane receptors 
(145-148).  It is likely that many second messenger systems such as the cAMP cascade and the 
phosphoionositide cascade, play a role in actions of membrane associated ERs (149-151).  It is 
important to remember that there is overlap between genomic and rapid signaling events in 
hormone mediated actions.   Therefore estrogen receptor expression and cellular localization are 
of primary importance in determining the specific effects of estrogen in any given cell (152). 
 
Effects of Estrogen on the Lipolytic Cascade 
To date, most studies investigating estradiol’s effects on lipolysis have been conducted in 
animal models, primarily in rats (153, 154).  These studies have generated the overlying 
hypothesis that estradiol serves to stimulate lipolysis.  Ovariectomy in rats leads to weight gain; 
E2 replacement reverses that trend as well as increases adenylyl cyclase activity (155).  In 
isolated rat adipocytes, E2 treatment increases cAMP and lipolysis, as measured by glycerol 
release, within 5 minutes (156).  In support of an alternative role of estrogen on lipolysis in 
animals, Pecquery et al. conducted a study in which estradiol decreased lipolysis in adipocytes 
from hamsters through a reduction in adenylyl cyclase activity (157).   
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Few in vivo human studies have been conducted that modulate local estrogen status while 
measuring real time changes in lipolytic rate.  We know of only one study acutely modulating 
hormonal status in vivo to investigate changes in whole body and regional lipolysis.  Van Pelt et 
al. found that acutely increasing circulating E2 concentrations with an intravenous bolus of 
exogenous estrogen in postmenopausal women decreased basal lipolysis in femoral SAT, and to 
a lesser extent in abdominal SAT, using the microdialysis technique.  These findings support 
estrogens in regional adipose metabolism and confirm an acute non-genomic effect of estrogen 
within the adipose tissue; at least on basal lipolysis (91). 
A few notable studies have been conducted in humans or using isolated human 
adipocytes to investigate the chronic or genomic effects of estradiol on lipolysis, with most 
finding estrogen associated with lower stimulated lipolysis.  Lindberg et al. isolated 
subcutaneous abdominal adipocytes from women before and after three weeks of oral ethinyl 
estradiol treatment, after which the adipocytes had decreased in vitro response to noradrenaline 
stimulated lipolysis in comparison to pretreatment (158).  More recently, when adipocytes 
isolated from subcutaneous adipose tissue fragments of healthy premenopausal women were 
incubated in E2 in vitro for 24 hours, glycerol release in response to epinephrine exposure was 
lower versus control conditions (159).  The blunted response to stimulated lipolysis after E2 
treatment is attributed to an increase in anti-lipolytic α2-AR expression.  Increased α2-AR 
expression is evident in subcutaneous adipocytes treated with E2 for 24 hours, as well as in 
postmenopausal women treated with estrogen replacement for 3 years (159).  On the other hand, 
estrogen treatment did not appear to have any effect on β-AR expression in SAT or α2-AR 
expression in VAT (159).  The differential response of α2-AR up-regulation between SAT and 
VAT served as some of the earliest evidence to potentially explain how E2 may have a 
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modulatory role in the maintenance the subcutaneous/gynoid fat patterning in women.  
Furthermore, α2-AR up-regulation with E2 treatment in human SAT could help explain the 
divergent results between rat and human studies, as rats do not express α2-ARs in adipose tissue.   
The primary adrenergic independent regulators of lipolysis in humans are insulin, 
adenosine, and ANP, but very few studies have investigated the potential role of estrogen in 
modulating these regulators of lipolysis.  The one previous study which has investigated the role 
of estrogens in insulin mediated suppression of lipolysis in postmenopausal women did not see 
an alteration in whole body, abdominal or femoral SAT insulin mediated suppression of basal 
lipolysis after an acute intravenous bolus of estrogen (91).  Both animal (160, 161) and human 
studies (162-164) have established an association between declines in circulating estrogen status 
and decreased circulating ANP levels as well as changes ANP-A receptor expression (165), but 
no mechanistic or depot specific effects of estrogen on ANP have been determined.   
In SKBR3 cells (an ERα/ERβ negative but estrogen sensitive breast cancer cell line) in 
vitro GPER is recognized in mediating E2-stimulated increases in cAMP and intracellular 
calcium, as well as E2-promoted proliferative signaling (166-168), but to our knowledge, its 
involvement in modulation of the lipolytic cascade is not known. 
 
Exercise-Stimulated Lipolysis 
Fat serves a main energy source during prolonged physical activity (169).  Low-to-
moderate intensity exercise (up to about 60% maximal oxygen uptake [VO2max]) increases fat 
oxidation on the whole body level, as well as increases mobilization of non-esterified fatty acid 
(NEFA) from the adipose tissue dramatically from what is seen at rest (170, 171).  It is believed 
that SAT (170) along with intramuscular triglycerides (172, 173) are the primary sources of fatty 
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acids mobilized by the adipose tissue during moderate intensity exercise for oxidation, with a 
lesser contribution from the visceral depot (170).  Importantly, only a very low intensity of 
exercise is required for significant increases in NEFA mobilization from abdominal SAT with 
further increases in exercise intensity leading to only small additional increases in NEFA 
mobilization (174, 175), if any at all (176).   
The exercise induced release of NEFAs from adipose tissue is potentially influenced via 
multiple pathways such as adipose tissue lipolysis, fatty acid re-esterification, and adipose tissue 
blood flow (102).  Decreased rates of fatty acid re-esterification play at least a small role in 
increased NEFA mobilization (172, 177).  Lipolysis is the major pathway through which 
increased NEFA mobilization is modified during exercise.  The traditional belief is that elevated 
catecholamine concentrations, as well as a small decrease in insulin concentration, are 
responsible for the exercise associated increase in lipolysis (69, 178).  Even low intensity 
exercise increases circulating epinephrine levels enough to stimulate SAT lipolysis (179).  
Although some research has indicated that circulating mediators are the most important 
activators of lipolysis (180), others have found that sympathetic innervation of the adipose tissue 
and neural activation also play important roles in activation of lipolysis (181).  The importance 
of catecholamine action on activation of β-AR receptors in SAT is demonstrated in the dramatic 
decrease (but not abolition) in exercise-induced lipolysis in young lean men and women 
undergoing selective β-AR blockade (69).  Furthermore, some level of lipid mobilization is 
maintained during exercise even when epinephrine action is blocked (182), further supporting 
the role for AR-activation to play a large, but not the only, role in exercise mediated increases in 
fat mobilization.   
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One possible alternative modulator in exercise induced lipolysis is ANP, which is 
secreted primarily from the atrial cardiomyocytes in response to mechanical stretch and during 
exercise is secreted in an intensity-dependent manner (174, 183, 184).  It is possible that the 
influence of ANP on exercise stimulated lipolysis is somehow related to regulation of adiposity 
(184).  Furthermore, as the duration of low-to-moderate intensity exercise increases the actions 
of hormones such as cortisol and growth hormone (185-187) may also be involved in the 
increase in whole body lipolytic rate (170) and regional specific adipose tissue lipolysis (180, 
188, 189) but more research is needed to determine the significance of these factors. 
 
Estrogen Regulation of Exercise-Stimulated Lipolysis 
Women utilize proportionally less carbohydrate and more lipid compared to men during 
exercise of mild to moderately high intensity (40-70% VO2max) (190).  Whole-body lipolysis 
appears to be higher, as measured by glycerol rate of appearance (Ra), for women compared with 
men during endurance exercise (191), and arterial glycerol levels in women are higher than men 
during the first 30 minutes of exercise (192), still, some studies have demonstrated no sex 
differences in circulating glycerol during exercise (190).  Interestingly, during exercise levels of 
epinephrine and norepinephrine do not rise as much in women as they do in men (190).  To 
explain this paradoxical relationship it is hypothesized that in women there is a greater sensitivity 
to the lipolytic action to one or both of the catecholamines leading to the equal or increased 
glycerol measured during exercise in women compared to men (190).  Although these sex 
differences in whole-body lipolysis are primarily attributed to differences in circulating sex 
hormones, the direct mechanism of action for estrogen on these differences has not been full 
elucidated.  
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Regional Differences in Exercise-Stimulated Lipolysis 
Given what is known about regional differences in basal lipolysis, adrenergic receptor 
density/sensitivity and adipose tissue blood flow, it is not surprising that there is a clear regional 
difference in exercise stimulation of lipolysis.  Microdialysis studies have revealed exercise 
induced lipolysis is greater in abdominal versus lower body (gluteal or femoral) SAT regardless 
of the mode of exercise (69, 180, 193), a depot dependent effect that is much more apparent in 
women than in men (69). Interestingly, this sex divergence is manifested in differences in 
abdominal lipolysis, demonstrated by a larger increase in dialysate glycerol in the abdominal 
region in women as compared to men in response to 30 minutes of submaximal exercise, while 
in the gluteal region the increase in dialysate glycerol induced by exercise was almost identical 
between women and men (69). Variation in catecholamine sensitivity between adipose tissue 
depots are believed to be the primary modulators of this regional difference (89, 194, 195), but 
other mechanisms such as regional sympathetic outflow (196), local blood flow, or other 
unknown factors cannot be dismissed from having a potential role.  
 
Conclusion of Literature Review 
Premenopausal women have a distinctive gynoid body fat distribution which is associated 
with lower disease risk than accumulation of central adiposity (6, 197, 198).  Circulating 
estrogen is recognized as playing a key role in determining regional adiposity, and the presence 
of estrogen producing enzymes (114) as well as estrogen receptors (119, 120) in adipose tissue 
supports a role for direct estrogen action within this tissue.  Importantly, there is strong evidence 
in animal models that estrogen may influence lipolytic rate (153, 199), but the in vivo evidence 
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from human trials is limited and much of it conflicts with previous results from animal studies 
(91, 158, 159, 200).   
African American premenopausal women accumulate less VAT and more SAT compared 
to Caucasian women of the same age and waist-to-hip ratio (22, 24).  Paradoxically, AA women 
also have more CVD risk factors and an increased incidence of diabetes and hypertension than 
CA women despite displaying what would be considered a more metabolically favorable body 
fat distribution (27, 28).  Racial differences in lipolysis, estrogen action within adipose tissue, or 
adipocyte size could be mechanisms involved in the divergent body composition and associated 
disease risk between CA and AA. 
 
Central Hypotheses 
The global aim of this project is to determine if local estrogens influence regional 
lipolysis in subcutaneous adipose tissue of premenopausal women.  This will be the first step in 
developing a more complete understanding of the mechanisms behind the influence of sex 
hormones on regional adiposity.  It is the main hypothesis of this project that exposure to high 
concentrations of estradiol will reduce lipolytic rate in SAT of premenopausal women, 
particularly in the gluteal region.  This would support a role for estradiol in mediating the 
preferential subcutaneous, and chiefly gynoid, body fat distribution of premenopausal women.  
Determining characteristics of the adipose tissue such as estrogen receptor expression and 
adipocyte size will also help in understanding differences in regional lipid metabolism.  Racial 
dissimilarities in regional adipose tissue accumulation and lipid metabolism lead to a 
complementary secondary aim for this project which is to conduct preliminary investigations 
into racial differences in estrogen action and adipose tissue characteristics such as estrogen 
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receptor content and adipocyte size between well-matched Caucasian and African American 
women.   
 
Specific Aim 1 
To determine if increasing the local subcutaneous adipose tissue E2 concentration 
will reduce lipolytic rate in abdominal and gluteal SAT of overweight-to-obese 
premenopausal women.  A secondary aim is to investigate if this effect of E2 is different 
between Caucasian and African American women.   
Lipolytic responsiveness in the gluteal-femoral region is typically lower than that of the 
abdominal region (201), but a full understanding of the mechanisms responsible for this regional 
difference remain unknown.  Discovery of estrogen receptors within the adipose tissue confirms 
that estrogen may directly modulate fat metabolism (119, 123-125).  Presently, measurement of 
SAT estradiol concentrations in humans is uncommon and the influence that this interstitial 
estrogen has locally on lipolytic rate in vivo is unknown.  Completion of aim 1 will result in a 
more clear understanding of the largely unknown and unrecognized physiological (or 
pathophysiological) role of estrogen within the adipose tissue in vivo in premenopausal women, 
and if this role differs between CA and AA premenopausal women.  Our hypothesis is that 
estradiol perfusion will decrease lipolysis, particularly in the gluteal region. 
 
Specific Aim 2 
To investigate regional differences in protein content of the estrogen receptors ERα, 
ERβ, and GPER within abdominal and gluteal subcutaneous adipose tissue of overweight-
to-obese premenopausal women.  A secondary aim was to determine if protein content of 
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these three estrogen receptors differs in Caucasian and African American premenopausal 
women. 
Confirmation of ERα, ERβ and GPER expression in adipose has provided evidence that 
estrogen has direct actions within this tissue (119-121, 124, 126).  This is the first study to report 
on protein content of all three major estrogen receptors from abdominal and gluteal subcutaneous 
adipose tissue of premenopausal women, creating a more complete picture of the potential 
pathways of estrogen action in adipose tissue.  Racial differences in ER content may give insight 
into mechanisms behind differences in regional adiposity between CA and AA women.  We 
hypothesize that ER content will be different between the abdominal and gluteal SAT, 
specifically that ERα content will be greater in the abdominal compared to gluteal region. 
 
Specific Aim 3 
 To characterize mean adipocyte size and adipocyte diameter distribution in adipose 
samples from abdominal and gluteal SAT of overweight-to-obese premenopausal women.  
A secondary aim was to investigate if there are racial differences in adipocyte size and 
diameter distribution between Caucasian and African American women. 
 Recent advances in adipocyte sizing techniques have revealed the importance of 
determining not only the ‘mean’ adipocyte size for a given depot, but also the relative frequency 
distribution of adipocytes from the sample (202, 203).  The size of an adipocyte is associated 
with lipolytic rate (204) and insulin sensitivity (205, 206) among other characteristics.  
Adipocyte diameter distribution comparisons are lacking between adipose tissue samples from 
the abdominal and gluteal SAT of overweight-to-obese premenopausal women, although an 
increased mean adipocyte size in the gluteal region is commonly reported in lower body obese 
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premenopausal women (93, 94).  Differences in adipocyte size distribution between upper and 
lower body adipose depots and Caucasian and African American women will allow for a more 
complete understanding of regional and racial differences in lipolysis and adipose metabolism.  
We hypothesize that adipocytes from the gluteal region will be larger than those from the 
abdominal region. 
 
Significance 
The maintenance of normal adipose tissue metabolism is vital to human health.  
Understanding the mechanisms responsible for regional adiposity can help in development of 
strategies to prevent increases in central adiposity in aging women.  The majority of research 
conducted on the association between obesity and disease risk is conducted in Caucasian women, 
but the elevated cardiometabolic disease risk and prevalence of diabetes in minority populations 
should not be ignored.  Uncovering the direct role estrogen holds within adipose tissue and in 
maintenance of the premenopausal gynoid body fat distribution may eventually contribute to 
development of techniques in prevention of the menopause associated increase in central 
adiposity and thereby also the increase in disease risk associated with that shift. 
  
 
 
CHAPTER 2: Estradiol Effect on Subcutaneous Adipose Tissue Lipolysis is Adipose Tissue 
Depot Specific and Treatment Dependent 
 
Abstract 
Regional differences in lipolytic rate have been implicated in preferential gynoid body fat 
distribution of premenopausal women.  Estrogen has direct effects within adipose tissue and has 
been implicated as a modulator of regional adiposity; however its influence on in vivo lipolytic 
rate in premenopausal women is unclear.  Therefore the purpose of this study was to investigate 
the effect of locally infused estradiol (E2) on subcutaneous adipose tissue (SAT) lipolytic rate in 
premenopausal women.  Our secondary aim was to investigate if the influence of E2 on lipolysis 
was different between well matched subgroups of Caucasian (CA) and African American (AA) 
women.  We measured in vivo lipolysis (indicated by dialysate glycerol) via microdialysis of 
subcutaneous AB and GL adipose tissue in 17 overweight/obese women (age: 27.4±2.0 yrs, 
BMI: 29.7±0.5 kg/m
2
) at basal and during perfusion of the β-adrenergic (AR) agonist 
isoproterenol (ISO; lipolytic stimulator through β-AR activation), co-perfusion of ISO with the 
α-AR antagonist phentolamine (PHEN; relieves inhibition of lipolysis by α-AR), and 
physiological stimulation by submaximal aerobic exercise.  Sixty-minutes of ISO perfusion 
resulted in a significant increase in dialysate glycerol from basal in all probes, with a 
significantly lower response in the GL region. Co-perfusion of E2 with ISO blunted the 
stimulatory response to ISO in the AB region (195.9±30.6% versus 257.7±26.0% p=0.003), but 
did not change the response in the GL region (112.7±13.9% vs 110.6±12.4%, p=0.43).  Thirty-
minutes of submaximal exercise during ISO + PHEN perfusion significantly increased dialysate 
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glycerol from ISO + PHEN at rest in all probes.  E2 perfusion enhanced the percent increase in 
dialysate glycerol in response to ISO + PHEN + exercise in the AB region (89.7±9.3% vs 
55.5±9.3%, p=0.007), but blunted the same response in the GL region (35.1±6.8% vs 
62.0±12.0%, p=0.05).  The effect of E2 perfusion was similar in CA and AA women.  These 
results indicate that E2 effects on lipolysis are region-specific and may work through both β-
adrenergic and potentially adrenergic-independent mechanisms to potentiate and/or blunt 
subcutaneous adipose tissue lipolysis in premenopausal women.   
 
Introduction 
Women have the propensity to accumulate more adipose tissue than men, particularly in 
the subcutaneous depot and gynoid region (34).  With age an increase in abdominal obesity is 
commonly demonstrated in women, diminishing the sex divergence in body fat distribution 
common in earlier years of life (207).  Reduced cardiometabolic disease risk in premenopausal 
women has been attributed to this differential body fat distribution (208) and the benign (8) or 
even protective effect of lower body adiposity (14, 209-211).  Alterations in the circulating 
hormonal milieu with menopause, such as the decline in circulating estrogens, have been 
implicated in age related shifts towards a central body fat distribution and cardiometabolic risk 
(44, 47). 
 Although associative data supporting the role of sufficient circulating estrogen in 
maintaining gynoid body fat distribution is available, mechanisms of sex steroid action within 
adipose tissue and how this may impact body fat distribution and lipid metabolism remain 
unclear.  Adipose tissue serves not only as a sink for hormones from the circulation, but also as 
an endocrine organ producing sex hormones which act in paracrine and autocrine fashion; more 
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recently termed intracrinology (116, 212).  The ability of adipose tissue to regulate 
concentrations of sex steroids locally reveals what may be an important evolutionary mechanism 
to help determine or regulate regional adiposity.  Of particular interest is the capacity of adipose 
tissue to produce estradiol (E2) through two routes: 1) aromatization of testosterone or 2) 
reduction of estrone by 17β-hydroxysteroid dehydrogenase (17β-HSD).  The discovery of  
estrogen receptor-α and -β (ERα and ERβ) (121, 123, 124), as well as the more recent detection 
of the G protein-coupled estrogen receptor (GPER) within human adipose tissue (126) further 
support the role of direct genomic and non-genomic actions of estrogens in maintaining 
homeostasis within adipose depots.  Furthermore, increased adiposity in estrogen receptor alpha 
and aromatase knockout models (αERKO and ARKO) (133, 213) confirm the significance of E2 
in maintenance of lipid homeostasis. 
The balance or imbalance of triacylglycerol accumulation and free fatty acid release 
(FFA) within a specific adipose depot is responsible for changes in local adiposity.  Decreased 
lipolytic rate in the gluteal depot of premenopausal women has been implicated in the increased 
adiposity demonstrated in this region (90, 214).  Moreover, acute intravenous administration of 
conjugated estrogens has been shown to decrease basal lipolysis in the abdominal and femoral 
subcutaneous adipose tissue of estrogen deficient postmenopausal women as measured by the in 
situ technique of microdialysis (91).  However, similar studies in premenopausal women 
examining acute modulation of lipolysis by 17β-estradiol (E2) are lacking.  Therefore, the 
purpose of this study was to investigate the effect of locally infused E2 on subcutaneous adipose 
tissue lipolytic rate in the abdominal and gluteal regions of overweight-to-obese premenopausal 
women.  A secondary aim of the study was to determine if the effect of estradiol was race-
dependent. 
 33 
 
 
Methods and Procedures 
Participants 
 Seventeen overweight/obese premenopausal women, (9 Caucasian/8 African American 
27.4±2.0 years, 81.7±2.3 kg, BMI 29.7±0.5 kg/m
2
) between 18 and 44 years old were studied.  
Participants enrolled in this study were eumenorrheic (average cycle length 30±1 days), not 
taking hormonal contraceptives (no use of hormonal contraceptives for at least 6 months at study 
entry), weight stable (< 3 kg weight change in the last 6 months) and sedentary, in that they did 
not engage in purposeful exercise training more than 30 minutes per day more than two days per 
week.  Women were excluded from the study if they were trying to get pregnant, were pregnant 
or lactating, a smoker, had history of diagnosis of any metabolic or cardiovascular disease, or 
were taking any medications known to alter lipid metabolism or blood flow.  Qualification for 
the study was determined by a pre-participation health history questionnaire completed by the 
participant and reviewed for accuracy with study personnel.  All participants were informed both 
verbally and in writing of the purpose, risks, and benefits of the research and provided informed 
consent prior to enrollment in the study.  This study was approved by the Medical Center 
Institutional Review Board at East Carolina University.  Participant characteristics are presented 
in Table 2.1.    
 
Study Design 
Initial visit.  Participants reported to the Fitness, Instruction, Testing, and Training (FITT) 
Facility of the Human Performance Lab at East Carolina University for their first study visit to 
obtain written informed consent and collect baseline information such as medical history, height, 
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weight, body composition measurements, waist and hip circumferences, and complete a maximal 
oxygen uptake (VO2peak) test of aerobic fitness.  Reported dates of menses for the previous 6-12 
months were recorded by study personnel to confirm eumenorrhea.  The microdialysis visit was 
subsequently scheduled according to the predicted start date of the next menstrual cycle; 
scheduling alterations were made if necessary to coincide with the early follicular phase of the 
menstrual cycle.  If previous records of menstrual cycles were not available, participants tracked 
the succeeding 2-4 menstrual cycles, reporting back to the study coordinator on the first day of 
menses.  
Body composition.  Participants were weighed on an electronic scale with weight 
recorded to the nearest 0.1 kg and height was measured with a standard stadiometer to the 
nearest centimeter (cm).  Minimal waist and hip circumferences were measured according to 
previously published guidelines and waist-to-hip ratio (WHR) was calculated (215).  Fat-free 
mass (lean mass + bone mineral content), whole body and regional fat mass (android, gynoid), 
and whole body percent body fat were determined using dual-energy x-ray absorptiometry 
(DXA; GE Lunar Prodigy Advance, Madison, WI).  The android region was bound on the lower 
border by the top of the iliac crest and on the upper border at a distance 20% of the distance 
between the top of the iliac crest and immediately below the chin; lateral borders were the arm 
lines.  The gynoid region was bound on the upper border at a distance 1.5 times the height of the 
android region and on the lower border at a distance 2 times the height of the android region; 
lateral boundaries were the outer leg lines.  
Maximal oxygen uptake exercise test (VO2peak).  The maximal exercise test was 
conducted on a Corival LODE cycle ergometer using a ParvoMedics TrueOne 2400 metabolic 
cart (Sandy, UT) for indirect calorimetry measurements.  Expiratory gasses were monitored 
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throughout the test and heart rate (polar hear rate monitor, Polar Electro Inc, Lake Success, NY) 
and blood pressure (manual measurements) were monitored during exercise and recovery.  
Resistance started at 25 watts and increased 15-25 watts every 2 minutes until volitional fatigue 
or the participant asked to stop for another reason.  The test was deemed successful by following 
the guidelines set forth by the American College of Sports Medicine (216).  One test did not 
meet the criteria for a maximal test and was repeated at a later date.   
Microdialysis visit.  Participants reported to the East Carolina Diabetes and Obesity 
Institute (ECDOI) at the East Carolina Heart Institute at 8am after an overnight (≥10 hour) fast 
during the follicular phase of the menstrual cycle (day 2-8 after day 1 of menses, one participant 
was completed on day 9).  On average, the microdialysis visit took place on day 5±1 of the 
menstrual cycle and cycle phase was confirmed by a blood draw the morning of the visit (Table 
2.2).  Food records were completed by all participants for the three days immediately preceding 
the microdialysis visit.  All participants rested in a semi-recumbent position for the duration of 
the study with the exception of the 30 minute stationary cycling session at the end of the visit and 
specific timepoints assigned for restroom breaks.  An indwelling polyethylene catheter (IV) was 
inserted into the antecubital vein for blood sampling.   
Blood was collected in lithium heparin or EDTA (Ethylenediaminetetraacetic acid) tubes 
for plasma or in untreated vacutainers for serum.  Plasma and serum were obtained by 
centrifugation, and aliquots were immediately stored at -80°C until later batch analysis to limit 
day to day assay variability.  Dialysate samples were collected every 15-30 minutes and blood 
samples were collected at baseline and immediately before and during/after the exercise bout.  
The first blood draw of the day (baseline) was used for determination of all baseline participant 
characteristics and confirmation of menstrual cycle phase.  Resting energy expenditure (REE) 
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measurements were made via indirect calorimetry (ParvoMedics TrueOne 2400 metabolic cart) 
for 25 minutes during the microdialysis visit while the participant was lying quietly undisturbed.  
The participants had been resting quietly for ~120 minutes after probe insertion before the REE 
measurement was made.  Data points from the first five minutes of the REE measurement were 
excluded from analysis to allow for subject equilibration; the remaining 20 minutes of data 
points were averaged for final REE values.  
The skin in a small area over the subcutaneous adipose tissue (SAT) region of interest 
was desensitized to pain using ethyl chloride spray and four microdialysis probes (CMA 20 MD 
Elite Probe 10 mm, 20 kDa cutoff, CMA Microdialysis/Harvard Apparatus, Holliston, MA) were 
first inserted unilaterally into the upper gluteal (GL) SAT ~3-10 cm right or left of the medial 
line of the buttock followed by insertion of four additional probes unilaterally into the abdominal 
(AB) SAT ~3-6 cm lateral to the umbilicus.  Probes in both regions were placed at least 2 cm 
from one another to avoid interference from adjacent probes and at a depth of approximately 
1cm into the SAT.  No sample was collected during the first hour post-probe insertion to allow 
for equilibration of the microdialysis system (217, 218).     
In vivo glycerol release (an indicator of lipolysis) was determined under basal conditions 
by continuously perfusing the microdialysis probes using CMA 107 microinfusion pumps (M 
Dialysis, N. Chelmsford, MA) at 2.0 µl/min with a 0.9% saline solution containing 10 mmol/l 
ethanol (for determination of local blood flow) (218, 219) which served as the base control 
solution for all stages of the visit.  After exchange with the SAT the pumped perfusate was 
collected at the exit end of the probe (dialysate) and stored at 4°C for analysis of ethanol (index 
of local blood flow) within 48 hours and subsequently stored at -20°C for later batch analysis of 
dialysate glycerol (index of lipolysis) and dialysate E2.  The experimental timeline for the 
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microdialysis visit is shown in Figure 2.1, but involved perfusion of isoproterenol (ISO, β-
adrenergic agonist; 1.0 µmol/l), phentolamine (PHEN, α-adrenergic antagonist; 0.1 mmol/l), 
and/or estradiol (E
2
; 500 nmol/l) (all from Sigma Aldrich, St. Louis, MO).  Previous 
microdialysis studies have demonstrated perfusion of these concentrations of ISO and PHEN 
induce maximal alterations in lipolysis (69, 80).  Furthermore, use of these pharmacological 
agents allow for specific adrenergic receptor targeted perturbations of lipolysis to gain a more in 
depth understanding through which adrenergic pathway estradiol may act to influence lipolysis.  
A 15 minute equilibration period was observed between stages to allow for full infiltration of the 
probe and surrounding SAT with the new perfusate solution. 
In the final portion of the visit (stage 5) participants were asked to cycle on a Monark 
Ergomedic 828E cycle ergometer for 30 minutes at 60% of their own previously determined 
VO2peak at a constant speed of 65 RPMs (revolutions per minute).  Submaximal exercise 
produces what is believed to be the one of, if not, the largest physiologic stimulus to increase 
adipose tissue lipolysis in humans and therefore was used within the current study to understand 
estradiol’s influence on physiological stimulation of lipolysis.  Heart rate was monitored 
throughout the exercise bout (polar hear rate monitor) and indirect calorimetry measurements 
(ParvoMedics TrueOne 2400 metabolic cart) were taken from the start of exercise until minute 
seven and repeated from minute 20 to minute 25 to confirm proper exercise intensity and steady 
state.  Exercise at 60% VO2max has previously been reported to elicit maximal lipolytic 
stimulation (220).  Two 15 minute dialysate samples were collected during the exercise bout.  
After completion of exercise all eight microdialysis probes were removed.  
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Sample Analysis 
Microdialysis samples and associated calculations.  Dialysate glycerol (Glycdialysate) 
(index of in vivo lipolysis) concentration was analyzed using a CMA/600 automated 
microdialysis analyzer (M Dialysis).  A concentration of 10 mmol/l ethanol has been shown to 
effectively detect blood flow changes around the microdialysis probe in SAT (221).  The ethanol 
outflow-to-inflow ratio (O:I) is inversely related to blood flow and was calculated:  
Ethanol Outflow:Inflow = [Ethanoldialysate] / [Ethanolperfusate] 
Dialysate and perfusate ethanol (indicator of local blood flow) was measured in our laboratory 
using a previously described enzymatic, fluorometric assay (218).   
In vitro studies previously conducted by our lab estimate the relative in vitro glycerol and 
ethanol recoveries over the microdialysis membrane to be 59.5±2.9% and 89.4±3.0% 
respectively at the flow rate of 2 µl/min through the CMA/Elite 10mm membrane probes used in 
both the in vivo and in vitro studies.  The following formula was used for the calculation of 
interstitial glycerol (GlycIS): 
GlycIS = [Glycdialysate] / ((1 - in vivo O:I)/(in vitro ethanolrelative recovery / in vitro glycerolrelative recovery)). 
Effects of E2 perfusion on stimulated/disinhibited lipolysis are presented as percent change from 
the Glycdialysate at the end of the previous stage to the Glycdialysate measured at the end of the stage 
of interest (i.e. % change in Glycdialysate = (( Glycdialysate 150min – Glycdialysate 90min)/Glycdialysate 
90min)*100).  Percent change in ethanol O:I between stages was calculated in the same manner.   
Dialysate estradiol was measured using a Salivary Estradiol ELISA (SLV-4188, DRG 
Instruments GmbH, Marburg, Germany). The intra-assay coefficient of variation (CV) was 2.2%.  
Interstitial estradiol (E2IS) was calculated identically to GlycIS, with in vitro recovery of E2 over 
the microdialysis membrane estimated by previous in vitro experiments in our laboratory to be 
 39 
 
21.5±4.3%.  The in vitro relative recovery rate of E2 and ethanol and in vivo relative recovery of 
ethanol were used to estimate the concentration of perfused E2 passing from the perfusate over 
the microdialysis membrane into the adipose tissue in vivo.  Our calculations determined that 
most likely 5-20% of the perfused E2 passed over the microdialysis membrane.  With the starting 
perfusate concentration at 500 nmol/l E2 we estimate the concentration of E2 passing into the 
local SAT surrounding the microdialysis probe to be ~25-100 nmol/l.  A volume of 2 µl/min of 
perfusate passed into the adipose tissue dispersing around a volume of interstitial fluid 
surrounding the 10mm x 0.5mm (length x diameter) probe.  Actual exchange of E2 over the 
membrane and local concentration is also dependent on local blood flow immediately 
surrounding the microdialysis probe.  
Blood samples.  Blood was drawn at three timepoints throughout the microdialysis visit: 
baseline, pre-exercise (~3.5 hours after baseline) and exercise (~1 hour after pre-exercise).  All 
blood measurements are listed in Tables 2.1, 2.2 and 2.7.  Missed blood draws or IV failures for 
some participants resulted in decreased sample size for repeated measures analysis of humoral 
factors.  Resting epinephrine was below the detection limit of the assay at baseline, but was 
measureable pre-exercise for most participants, consequently pre-exercise was used as the only 
resting epinephrine measurement.  Exercise blood sampling was completed during the exercise 
bout, within 5 minutes of termination for seven participants; however, due to difficulty with the 
blood collection during the cycling bout, samples for five participants were drawn immediately 
post exercise.  Unfortunately neither pre- nor post-exercise blood samples were obtained from 
five participants.   
Fasting serum samples of glucose, total cholesterol (TC), triglycerides (TG), and high-
density-lipoprotein (HDL) cholesterol were determined using enzymatic/colorimetric methods, 
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and low-density-lipoprotein (LDL) cholesterol was calculated using the Friedewald equation 
(222).  Fasting serum E2, follicle stimulating hormone (FSH), luteinizing hormone (LH), 
progesterone, testosterone, cortisol, and insulin were determined by Electrochemiluminescence 
Immunoassay (UniCel® DxC 600i Synchron® Access® Clinical System, Beckman Coulter, 
Inc., Brea, CA).  Homeostasis model assessment of insulin resistance (HOMA-IR) was 
calculated using the following equation [fasting glucose (mmol/l) x fasting insulin (µU/ml)]/22.5 
(223).   
Plasma glycerol (collected in lithium heparin) was determined in our laboratory using the 
Sigma quantitative enzymatic free glycerol determination kit (F6428 – Sigma-Aldrich Corp, St. 
Louis, MO).  Serum free fatty acids (FFA), estrone, and plasma catecholamine measurements 
were performed by the University of Colorado Denver Clinical and Translational Research 
Center (CTRC) Core laboratory. FFA were determined by enzymatic colorimetric methods 
(Wako Diagnostics USA, Richmond, VA; Intra-assay CV 1.1%, Inter-assay CV 5.6%), estrone 
was measured by conventional radioimmunoassay (Diagnostic Systems Laboratories, Webster, 
TX; Intra-assay CV 8.7%, Inter-assay CV 11.7%) and epinephrine (Epi) and norepinephrine 
(NE) (collected in EDTA) were determined by high-performance liquid chromatography (HPLC) 
(BioRad, Hercules, CA; Intra-assay CV: Epi 5.2%, NE 4.1%; Inter-assay CV: Epi 5.4%, NE 
5.4%).   
 
Statistics 
 The skewed distribution of TG, circulating estradiol, estrone, and progesterone 
necessitated logarithmic transformation of these data; the re-exponentiated geometric mean and 
95% confidence interval are presented.  Paired t-tests were conducted to determine regional 
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differences in basal blood flow, dialysate and interstitial glycerol, dialysate and interstitial 
estradiol, and adipocyte diameter.  Repeated measures ANOVA were conducted to determine 
changes in circulating factors throughout the study day as well as differences in dialysate 
glycerol values between stages.  Two-way repeated-measure ANOVA tests (region x time, 
region x probe) were used to determine regional differences in dialysate glycerol response to 
pharmacological and physiological stimulated lipolysis with and without estradiol co-perfusion.  
When indicated by a significant F statistic, post hoc analyses to determine significant mean 
differences between the groups were conducted by t-tests with bonferroni correction for absolute 
differences in dialysate glycerol between stages or Newman-Keuls analyses for differences in 
percent change between stages.  Three way ANOVA (race x probe x region) was used for 
preliminary analyses to determine racial and regional differences in dialysate glycerol response 
to pharmacological and physiological stimulated lipolysis with and without estradiol co-
perfusion.  Three way ANOVA (probe x time x region) was also used to determine probe and 
regional differences in dialysate glycerol percent change from baseline during basal (resting), 
exercise, and pharmacological perfusion.  Analyses were completed using IBM SPSS statistics 
version 19.  All data are presented as mean ± standard error (SE) unless otherwise noted, and 
alpha was set at 0.05. 
 
Results 
Participant Characteristics 
Participant characteristics are presented in Table 2.1 and gynecologic and baseline sex 
hormones in Table 2.2.  Baseline sex hormone concentrations confirmed all women were in the 
follicular phase of the menstrual cycle on the day of the microdialysis visit.  Two African 
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American participants exhibited elevated circulating estradiol, estrone, and LH values, indicative 
of late follicular phase timing immediately preceding ovulation rather than the early-mid 
follicular phase timing of the other participants.  However, neither FSH nor progesterone was 
significantly elevated in these two women; indicating ovulation had not yet occurred.  
Preliminary analyses of the data from these two participants revealed results consistent with the 
remainder of the study sample; therefore data from these participants has been included in all 
analyses.  Inclusion of these two women resulted in higher baseline LH in the AA versus CA 
women (Table 2.2; p=0.03).  Calculation of the mean LH value excluding these two women 
resulted in similar LH values between AA and CA women (data not shown).   
Abdominal and gluteal interstitial E2 concentration was determined from pooled dialysate 
samples consisting of dialysate from all basal timepoints in all four probes in each region in 13 
women.  Interstitial E2 concentration was similar in the abdominal and gluteal SAT and CA and 
AA women (Table 2.2) but is higher than the normal circulating range for E2 during the follicular 
phase of the menstrual cycle.  This measurement also provided confidence that the concentration 
of E2 perfused into the adipose tissue as part of the microdialysis protocol was of sufficient 
concentration to increase local SAT E2 levels from basal concentrations. 
Three day dietary analysis revealed that on average participants in the study consume 
2003±155 kilocalories (kcal) per day, consisting of 49.1±2.2% carbohydrate, 13.7±0.6% protein, 
and 37.1±2.2% fat.  There were no racial differences in total kcal/day (CA: 2143±244 kcal, AA: 
1846±184 kcal; p=0.36), or percentage carbohydrate (CA: 49.8±2.9%, AA: 48.3±3.7%; p=0.74), 
protein (CA: 14.5±1.0%, AA: 12.7±0.7%; p=0.18), or fat (CA: 35.7±2.5%, AA: 38.6±3.9%; 
p=0.54).   
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Resting and Exercise Metabolic Characteristics 
Metabolic characteristics are presented in Table 2.3.  Women successfully exercised at 
~60% of previously determined VO2peak for 30 minutes to physiologically stimulate lipolysis 
(stage 5 of microdialysis).  Performing submaximal exercise elicited a significant increase in 
absolute fat oxidation, respiratory exchange ratio (RER), and heart rate in all women (Table 2.3, 
p<0.001 vs resting).  VO2 (ml/kg/min) during submaximal exercise was lower in AA compared 
to CA women (Table 2.3).  This was likely due to the slightly lower (although not statistically 
different) VO2peak between the groups.  Importantly, percentage of VO2peak reached during the 
submaximal exercise bout was similar between races (Table 2.3) and therefore so was relative 
exercise intensity. 
 
Regional Differences in Basal Interstitial Glycerol  
Pooled group of participants.  In the basal state average Glycdialysate (pooled from all basal 
timepoints from all four probes) was not different in the abdominal and gluteal regions (AB 
34.0±1.9 µmol/l; GL 35.0±1.5 µmol/l; p=0.58), however, mean outflow-to-inflow ratio from the 
same timepoints was significantly higher in the gluteal region (AB 0.79±0.01; GL 0.85±0.01; 
p=0.001).  Calculation of GlycIS did reveal a significantly higher interstitial glycerol 
concentration in the gluteal region versus the abdominal region (AB 200.1±29.7 vs GL 
425.8±38.1 µmol/l; p=0.007).  Raw data for GlycIdialysate and O:I ratios for each stage and probe 
for the pooled population can be found in Tables 2.4 and 2.5 respectively.  Glycdialysate decreased 
throughout the microdialysis study day in all control probes similarly between the abdominal and 
gluteal regions (Figure 2.2A). 
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Racial comparison.  Caucasian and African American women had similar dialysate and 
interstitial glycerol values in both the abdominal and gluteal regions (CA: AB 34.2±2.7 µmol/l, 
GL 35.1±1.9 µmol/l; AA: AB 33.7±2.8 µmol/l, GL 34.9±2.5 µmol/l; race x depot p=0.93).  
There was a tendency for the gluteal interstitial glycerol to be higher than the abdominal in both 
the CA and AA women (CA: AB 315.4±46.5 µmol/l, GL 452.1±54.9 µmol/l p=0.07; AA: AB 
289.9±37.6 µmol/l, GL 396.2±54.1 µmol/l p=0.06).  The lack of a significant difference between 
the regions was most likely due to a lack of statistical power with the reduced sample size for the 
racial comparison; therefore all results of racial analyses must be considered preliminary 
investigations.  Both races demonstrated a significantly higher O:I in the gluteal versus 
abdominal region (CA: AB 0.79±0.01 vs GL 0.86±0.01 p=0.004; AA: AB 0.79±0.02 vs GL 
0.83±0.02 p=0.04) .    
 
Glycerol Response to Physiological and Pharmacological Modulation 
Fifteen minutes of submaximal cycle ergometry exercise was sufficient to increase 
Glycdialysate versus resting in both the abdominal and gluteal regions.  At 30 minutes of exercise 
Glycdialysate remained elevated versus resting in all probes (Figure 2.2A).  The increase in 
Glycdialysate with exercise was lower in the gluteal compared to abdominal region (Figure 2.2A).   
Thirty minutes of ISO perfusion also significantly increased Glycdialysate versus baseline in 
the abdominal and gluteal regions.  Glycdialysate remained elevated from basal in all probes at 60 
minutes of ISO perfusion.  Lipolytic stimulation due to ISO perfusion was lower in the gluteal 
compared to the abdominal region (Figure 2.2B).  Glycdialysate did not change from ISO perfusion 
alone after the addition of PHEN to the perfusate in either the abdominal or gluteal region 
(Figure 2.2B).  Thirty minutes of submaximal exercise during ISO + PHEN perfusion was able 
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to further increase Glycdialysate from its concentration during ISO + PHEN perfusion alone (Figure 
2.2B). 
 There were no significant racial differences in the responses to pharmacological and/or 
exercise stimulation of lipolysis.  Exercise (probe x time x race p=0.13), pharmacological 
modulation (probe x time x race p=0.5). 
 
Effect of Local Estradiol Perfusion on Adipose Tissue Glycerol 
Basal.  In the pooled group basal resting Glycdialysate measured via microdialysis was not 
affected by 180 minutes of perfusion of E2 compared to measurements from control probe over 
the same time period in the abdominal or gluteal region (Figure 2.3A).  There was a net effect for 
Glycdialysate to decrease throughout the study day in all four probes.  Preliminary analyses 
revealed a tendency for a racial difference in response to prolonged estrogen perfusion at rest 
(probe x time x race, p=0.06); estradiol tended to blunt the decrease in dialysate glycerol over 
time in the Caucasian group, but not the African American group (Figure 2.3B and C).  Limited 
power in these racial analyses restricts our ability to draw definite conclusions about potential 
racial differences.  
Exercise.  Perfusion of E2 did not alter the increase in Glycdialysate in response to 30 
minutes of cycle ergometry exercise compared to a no-E2 (control) perfused probe in either the 
abdominal or gluteal region.  The Glycdialysate response to exercise was lesser in the gluteal 
region, but this diminished response was not different between control and E2 probes (Figure 
2.4A).  There was no racial difference in the response to exercise, with or without estradiol 
perfusion (Table 2.6; depot x probe x race p=0.68). 
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Isoproterenol.  SAT dialysate glycerol increased with perfusion of ISO (β-AR agonist) in 
the abdominal and gluteal regions.  The effect of E2 co-perfusion along with ISO on glycerol 
release was dependent on adipose tissue depot (probe x region p=0.003).  In the abdominal 
region the addition of E2 to the ISO perfusate resulted in a significantly blunted increase in 
Glycdialysate compared to ISO perfusion without E2 (Figure 2.4B; p=0.003).  The increase in 
Glycdialysate in response to ISO perfusion was lower in the gluteal compared to abdominal region, 
and this response was not different between the control and E2 probes (Figure 2.4B, p=0.428).  
There were no racial differences in the response to ISO perfusion alone or with co-perfusion of 
E2 (Table 2.6; depot x probe x race 0.09).   
Isoproterenol and phentolamine.  The addition of PHEN (α-AR antagonist) on top of ISO 
in the perfusate for 60 minutes did not significantly change local glycerol release in any of the 
probes (with or without co-perfusion of E2 in AB or GL regions) as indicated by no change in 
Glycdialysate concentration from ISO perfusion alone (Figure 2.4C).  The same was true when 
analyses were broken down individually for Caucasian and African American women (Table 2.6; 
depot x probe x race p=0.38). 
Isoproterenol, phentolamine, and exercise.  Modulation of lipolysis by the addition of 
physiological stimulation (30 minutes of submaximal exercise) to ISO + PHEN perfusion (i.e. 
‘maximal’ stimulation) resulted in a significant increase in Glycdialysate from ISO + PHEN 
perfusion alone.  Glycdialysate measured from probes perfused with E2 during ISO + PHEN + 
exercise responded divergently dependent on the region of interest (Figure 2.4D; probe x region 
p=0.001).  In the abdominal region the percent increase in Glycdialysate after 30 minutes of 
exercise along with ISO + PHEN perfusion the E2 co-perfused probe was significantly greater 
than the increase in the control probe (p=0.007), whereas in the gluteal region, the E2 perfused 
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probe had a smaller percent increase in Glycdialysate versus the control probe (p=0.054) (Figure 
2.4D).  The Glycdialysate response was similar between control probes in the abdominal and gluteal 
regions.  Once again, there was no difference in the response to modulation with or without E2 
perfusion between the racial groups (Table 2.7; depot x probe x race p=0.18). 
 
Adipose Tissue Blood Flow 
 Blood flow was monitored indirectly by outflow-to-inflow ratio throughout the 
microdialysis visit; raw data for all probes and timepoints for the pooled group can be found in 
Table 2.5.  Percent change in O:I was calculated between stages to coincide with changes in 
dialysate glycerol over the same time periods (Figure 2.5 A-D).  The percent decrease in O:I 
ratio did not differ between probes or regions during the ISO perfusion in stage 3 (Figure 2.5B), 
or during ISO + PHEN + exercise in stage 5 (Figure 2.5D).  Exercise alone (stage 5, probes 1 
and 2) increased blood flow surrounding the probe perfused with E2 in the gluteal region, but did 
not change blood flow in the control probe in the same region or in either probe in the abdominal 
region (Figure 2.5A; region x probe, p=0.048).  Co-perfusion of E2 during the ISO + PHEN stage 
(stage 4) resulted in a significant decrease in local blood flow in the abdominal region, as 
indicated by an increase in O:I ratio versus the control probe (Figure 2.5C; main effect of E2, 
p=0.009).  This change in blood flow was not evident in the gluteal region.  
 There was no main effect of race on change in O:I ratio during exercise (race x probe 
p=0.88), ISO alone (race x probe p=0.78), ISO + PHEN (race x probe p=0.38), ISO + PHEN + 
exercise (race x probe p=0.56).  
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Circulating Humoral Factors  
All blood values were similar between the two resting blood draws (baseline and pre-
exercise) with the exception of an increase in circulating testosterone (Table 2.7).  The values of 
most circulating factors from participants sampled post-exercise instead of during-exercise were 
similar and were combined into a single exercise timepoint (Table 2.7; n=7 during-ex + n=5 
post-ex = n=12 exercise).  The exceptions to this were insulin, which was lower, and 
norepinephrine, which was higher, when sampled during exercise compared to post-exercise 
(Table 2.7, both p<0.05).  Therefore insulin and norepinephrine were kept separate during- and 
post-exercise timepoints for analysis.  Exercise significantly increased all blood values in the 
pooled samples, except for estradiol, which did not change.  Blood values were similar between 
races at all timepoints except for glucose at the exercise draw which was higher in the AA (CA: 
4.6±0.15 mmol/l vs AA: 5.2±0.16 mmol/l, p<0.05).  
 
Discussion 
 This is the first study to locally modulate the subcutaneous adipose tissue (SAT) sex 
steroid profile to determine how changes in E2 may directly affect lipolysis.  The novel finding 
of this study is that increasing the local SAT E2 concentration does indeed change local lipolytic 
rate as measured via the in situ technique of microdialysis, reinforcing a modulatory role for 
estradiol in female adipose tissue metabolism.  Importantly, our results indicate that the influence 
of E2 is dependent upon the adipose tissue depot of interest as well as the specific regulatory 
mechanism targeted.  We found that the β-adrenergic receptor mediated increase in lipolysis is 
blunted by estradiol (as indicated by smaller percent change in dialysate glycerol) in abdominal 
SAT, but is not affected in gluteal SAT.  In addition, we demonstrated that estradiol blunts the 
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lipolytic response to ‘maximal’ stimulation in gluteal SAT while simultaneously increasing the 
lipolytic response to ‘maximal’ stimulation in abdominal SAT.  Maximal stimulatory conditions 
consisted of pharmacological modulation (with local α-AR blockade and β-AR stimulation) 
coinciding with physiological stimulation (via submaximal exercise).  Finally, we showed 
preliminary evidence that race does not appear to influence the effect of estradiol on stimulated 
lipolytic rate, but may alter estrogen’s effect on basal lipolysis.  Our variable findings within a 
single controlled study demonstrate the importance of specificity when investigating and 
reporting effects of estradiol on adipose tissue metabolism in women and may help clarify the 
heterogeneous results reported in previously published literature in this area.  
 Investigations utilizing isolated adipocytes in vitro and FFA release tracers in vivo in 
premenopausal women have established metabolic differences between adipocytes from gluteal-
femoral versus abdominal SAT with the lower body regions being less lipolytically responsive 
(87, 88, 90, 93, 94, 224). Increased insulin sensitivity and α2-AR receptor expression are 
believed to promote triacylglycerol storage and inhibit lipolysis in the gluteal-femoral region 
(88), potentially playing a central role in the accumulation of lower body adiposity in 
premenopausal women.  Specifically, increased α2-AR receptor expression leads to a reduced 
lipolytic effect of catecholamines in gluteal-femoral adipose tissue (87, 214).  In agreement with 
this previous research, the current study also clearly demonstrates a blunted response to 
stimulated lipolysis in gluteal SAT under two conditions: 1.) β-AR agonist perfusion and 2.) 
submaximal exercise alone (believed to be primarily catecholamine mediated).  It is possible that 
the preference for adipose storage in the gynoid region serves a specialized function in 
premenopausal women; accumulating energy stores for future utilization during pregnancy and 
lactation (94).  Lower lipolytic response in the gluteal region may also be involved in the lack of, 
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or possibly negative, relationship between lower body obesity and cardiometabolic disease risk 
(5, 6, 16-19).  Sequestering circulating lipids and releasing fewer free fatty acids into circulation 
may help to protect women with a propensity for storing adipose in the gluteal-femoral region 
from excess exposure to circulating lipids and the negative health consequences associated with 
them (i.e atherosclerosis, insulin resistance, diabetes, etc.).  It is possible that local E2 exposure 
may also play a role in regional differences in lipolytic rate and the preferential storage of 
adipose in the SAT depot in women.  The importance of understanding estrogen action in 
adipose tissue is underscored by the fact that adipose tissue is an estrogen producing organ, 
particularly in postmenopausal women where adipose tissue is the major site of estrogen 
production (225). 
 
Effects of E2 on Basal Lipolysis 
Studies involving acute effects of estradiol on lipolysis are lacking.  We know of only 
one other study acutely modulating hormonal status in vivo to investigate changes in whole body 
and regional lipolysis and it was conducted in postmenopausal, rather than premenopausal, 
women.  Van Pelt et al. found that acutely increasing circulating estradiol concentrations with an 
intravenous bolus of exogenous conjugated estrogens decreased basal lipolysis as determined 
using the microdialysis technique in SAT in the femoral region, and to a lesser extent in the 
abdominal region, supporting a role for estrogens in regional adiposity (91) and suggesting  a 
potentially non-genomic effect of estradiol on basal lipolysis within the adipose tissue in 
humans.  We were unable to detect an effect of estradiol perfusion on basal lipolysis in the 
present study, which was surprising considering the previous findings revealing a role for 
estradiol to decrease basal lipolytic rate within 90 minutes of the IV bolus (91).  However, the 
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previous study was conducted in estrogen deficient postmenopausal women whereas the current 
study was conducted in normal, healthy, estrogen replete premenopausal women in which 
perfusion of supplementary estradiol may not lead to further alterations in an already estrogen 
saturated basal lipolytic pathway.  It is also possible the mode of estrogen administration (SAT 
perfusion compared to IV bolus) could explain the differential results.  The tendency for a racial 
difference in the response to E2 perfusion during basal lipolysis measurements may have 
diminished our ability to clearly demonstrate an effect of estradiol on basal lipolysis.  Further 
investigations are necessary to uncover if estradiol does in-fact depress basal lipolysis and if this 
differs in Caucasian and African American women, as our preliminary investigations suggest.  
  
Effects of E2 on Stimulated/Disinhibited Lipolysis  
The first study to find exogenous steroids influenced stimulated lipolysis in humans 
involved a three week oral ethinyl estradiol treatment in overweight estrogen deficient 
postmenopausal women (158).  Estrogen replacement in these women led to a decrease in 
norepinephrine stimulated lipolysis in adipocytes from the abdominal, but not gluteal, SAT 
compared to pretreatment values (158), providing evidence that estradiol may decrease lipolysis 
in subcutaneous adipose tissue of women in a region specific manner.  Additional investigations 
have found that postmenopausal women on chronic estrogen replacement demonstrate a trend for 
lower hormone sensitive lipase (HSL) activity and increased α2-AR mRNA expression 
compared to a placebo treated group (159).  In the same study, abdominal SAT samples from 
estrogen deplete postmenopausal women incubated in vitro for 24 hours with estradiol resulted 
in increased α2A-AR expression as well as a blunted lipolytic response to epinephrine, with no 
change in β-AR expression, versus control-treated adipose samples; potentially implicating the 
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increase in α2-AR expression in the decreased lipolytic response to epinephrine (159).  In the 
present study acute SAT perfusion of estradiol led to blunting of lipolysis through a β-AR 
mediated mechanism, as demonstrated by reduced lipolytic responsiveness to ISO perfusion 
when estradiol was on board in the abdominal, but not gluteal, SAT.  The addition of the α-AR 
blocker PHEN did not change the lipolytic response to ISO perfusion with or without estradiol 
co-perfusion in either depot; therefore, it does not appear that α-AR inhibition of lipolysis is 
involved in the E2 modulation of ISO-stimulated lipolysis.  The influence of E2 specifically on α-
AR inhibition of lipolysis cannot be determined from the current study design and future studies 
are warranted.  As a whole, the results from the current and previous studies establish that 
estradiol can work through multiple adrenergic receptor mediated mechanisms to dampen 
lipolytic rate in subcutaneous abdominal adipose tissue of both pre- and post-menopausal 
women, potentially helping to maintain a subcutaneous adipose distribution in an estrogen 
replete population, and increase abdominal adipose accumulation in a postmenopausal 
population. 
 
Depot Dependent Effects of E2. 
 Of particular interest is our observation of a divergent response to estradiol perfusion in 
the abdominal and gluteal SAT.  As discussed earlier, differences in lipolysis between the 
abdominal and gluteal-femoral regions in premenopausal women are well known and are 
believed to play a role in maintaining the gynoid body fat distribution in this population (93).  
Estradiol has also clearly been demonstrated to modulate lipolysis both in acute and chronic 
exposure conditions, with some limited evidence for regional differences in these effects (91, 
158).  Our study clearly provides evidence that estradiol’s influence on lipolysis occurs in a 
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region specific manner.  First, we found E2 blunts ISO stimulated lipolysis in the abdominal 
region but not the gluteal region.  Secondly, we found that E2 blunts lipolysis in the gluteal 
region, but potentiates lipolysis in the abdominal region during ‘maximally’ 
stimulated/disinhibited conditions.  Because previous investigations have demonstrated the 
perfusion of ISO and PHEN at the concentrations used in this investigation lead to maximal 
changes in lipolysis (69, 80) we believe that further increases in lipolysis with the addition of 
submaximal exercise along with perfusion of these pharmacological agents was most likely due 
to non-adrenergically mediated mechanism(s).  We do however recognize the possibility that 
some, or all, of the additional stimulation of lipolysis could be a result of further catecholamine 
stimulation of the β-ARs.  We hypothesize that the divergent regional effects of estradiol on 
lipolysis during ‘maximal’ stimulation occur through a yet to be determined adrenergic 
independent mediator of lipolysis.  Through this yet to be determined pathway estradiol may be 
acting in a region specific manner to help maintain the gluteal-femoral body fat distribution in 
premenopausal women during times of increased lipid mobilizing signals.  Furthermore, it 
appears estrogen acts through multiple mechanisms to influence lipolysis in a region specific 
manner. 
Atrial natriuretic peptide, insulin, adenosine, cortisol, and nitric oxide are all well-known 
non-adrenergic regulators of lipolysis through which estrogen may potentially influence local 
lipolytic rate.  It is also possible that alterations in second messenger systems such as the cyclic 
adenosine monophosphate (cAMP) cascade and the phosphoionositide cascade, play a role in 
actions of membrane associated ERs (149-151).  More studies are necessary to fully elucidate the 
direct actions of estradiol on lipolysis and the mechanisms behind this influence, particularly 
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estrogen’s actions through the three known adipose tissue estrogen receptors and its influence on 
both adrenergic and non-adrenergic modulators of lipolysis. 
 
Adipose Tissue Blood Flow  
Changes in adipose tissue blood flow must be considered when using microdialysis to 
study local lipolysis. The use of the ethanol technique provides a qualitative assessment of 
changes in microvascular exchange (nutritive blood flow), a key determinant in the concentration 
of substances recovered in the dialysate over the microdialysis membrane.  In the current study, 
the gluteal SAT exhibited lower blood flow/microvascular exchange when compared to the 
abdominal region, indicating reduced tissue exposure to circulating hormones and humoral 
factors and decreased metabolic clearance in the gluteal adipose depot.  These mechanisms could 
play a role in the decreased responsiveness to metabolic perturbations such as catecholamine 
stimulation during exercise in the gluteal-femoral region.  Estradiol perfusion per se did not 
change SAT blood flow considerably in our study, even though estrogen is known to have 
vasodilatory effects (i.e. increase blood flow) in large vessels and even the coronary 
microvasculature in postmenopausal women (226-228).  However, acute changes in circulating 
estrogen levels (i.e. the menstrual cycle) do not affect microvascular responses in normally 
cycling premenopausal women (229), consistent with our current findings with little change in 
blood flow around the probe with estradiol perfusion in SAT.  Only under two conditions did the 
estradiol probe have a significantly different blood flow response than the no-estradiol probe, 
manifested in a lower blood flow than around the control probe in the abdominal region during 
ISO+PHEN perfusion and a higher blood flow than around the control probe in the gluteal region 
during exercise.  Changes in blood flow with estradiol perfusion were inconsistent by both 
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region and stage and were not apparent during any stage in which estradiol had a significant 
effect on lipolysis, making it unlikely that observed changes in lipolysis were simply a result of 
changes in local blood flow. 
 
Conclusions 
In conclusion, this study suggests that exposure to high concentrations of estradiol leads 
to region and pathway dependent modulation of subcutaneous adipose tissue lipolysis in 
premenopausal women.  Estradiol blunts β-adrenergic stimulation of lipolysis in the abdominal, 
but not gluteal, SAT of premenopausal women, possibly implicating local adipose estrogen 
concentrations in modulating abdominal SAT accumulation.  In addition, estradiol may also have 
a potentiating effect on lipolysis in the abdominal SAT, but a suppressive effect on lipolysis in 
the gluteal SAT, when lipolysis is ‘maximally’ stimulated via potentially non-adrenergically 
mediated mechanisms.  These divergent regional responses apparent with increased estrogen 
exposure may be involved in the maintenance of the gynoid body fat distribution in 
premenopausal women even during times of increased lipid mobilizing signals.  Limited data 
infer that race does not appear to be a determining factor in the effect of estradiol on stimulated 
lipolysis in premenopausal women; however preliminary evidence suggests it may influence 
estrogen’s effect on basal lipolysis.  Our results shed light on why previous studies have 
demonstrated conflicting results in regards to pro- or anti-lipolytic effects of estradiol in adipose 
tissue of women.  When investigating estrogen mediated modulation of lipolysis particular 
attention must be paid with regards to the specific lipolytic regulatory pathways as well as the 
adipose tissue depot(s) under investigation. 
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Table 2.1  Participant Characteristics
Variable Pooled Caucasian African American
n 17 9 8
Age, yrs 27.4 ± 2.0 27.2 ± 2.9 27.6 ± 2.8
Weight, kg 81.7 ± 2.3 81.1 ± 2.0 83.4 ± 4.6
BMI, kg/m
2
29.7 ± 0.5 29.3 ± 0.6 30.3 ± 0.9
Waist Circumference, cm 89.3 ± 1.1 88.7 ± 1.5 90.0 ± 1.9
WHR 0.79 ± 0.01 0.79 ± 0.02 0.79 ± 0.01
Body fat, % 47.3 ± 1.0 46.0 ± 0.8 48.8 ± 2.0
Android Fat Mass, kg 3.1 ± 0.3 3.1 ± 0.2 3.1 ± 0.3
Gynoid Fat Mass, kg 7.0 ± 0.3 7.0 ± 0.3 7.0 ± 0.5
Total Cholesterol, mmol/l 3.9 ± 0.1 3.8 ± 0.2 4.0 ± 0.2
HDL Cholesterol, mmol/l 1.3 ± 0.1 1.3 ± 0.1 1.2 ± 0.1
LDL Cholesterol, mmol/l 2.2 ± 0.1 2.1 ± 0.2 2.4 ± 0.1
Triglycerides, mmol/l # 0.73 (0.57-0.93) 0.78 (0.52-1.17) 0.67 (0.47-0.96)
Fasting Glucose, mmol/l 4.8 ± 0.1 4.9 ± 0.1 4.7 ± 0.1
Fasting Insulin, pmol/l 55.0 ± 5.5 58.8 ± 6.7 50.8 ± 9.3
HOMA-IR 1.7 ± 0.2 1.8 ± 0.2 1.5 ± 0.3
Data are presented as mean±SE unless otherwise indicated.  # Skewed variable, re-
exponentiated to geometric mean and 95% confidence interval.  BMI, body mass index; 
WHR, waist-to-hip ratio; HDL, high density lipoprotein; LDL, low density lipoprotein; 
HOMA-IR, Homeostasis model assessment of insulin resistance. 
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Variable Pooled Caucasian African American
n 17 9 8
Cycle length, days 30.4 ± 0.7 31.2 ± 0.7 29.5 ± 1.3
Age at Menarche, yrs 11.7 ± 0.3 11.4 ± 0.4 12.0 ± 0.5
Parity, yes/no 4/13 3/6 1/7
Past HC use, n yes/no 7/10 5/4 2/6
Time since HC use, yrs 5.6 ± 2.5 6.4 ± 3.5 3.5 ± 0.5
Estradiol, pmol/l # 226 (147-348) 181 (112-292) 290 (124-678)
Estrone, pmol/l # 223 (172-288) 205 (156-269) 242 (145-405)
Progesterone, nmol/l # 0.36 (0.24-0.54) 0.34 (0.20-0.59) 0.39 (0.19-0.82)
Testosterone, nmol/l 1.08 ± 0.13 1.20 ± 0.2 0.95 ± 0.2
FSH, Iµ/l 7.3 ± 0.9 5.9 ± 0.5 8.9 ± 1.7
LH, Iµ/l 5.6 ± 0.9 3.5 ± 0.2 7.8 ± 1.6*
Interstitial Estradiol Abdominal, pmol/l # 
a 415 (220-783) 397 (159-281) 437 (163-1169)
Interstitial Estradiol Gluteal, pmol/l # 
a 380 (268-540) 452 (281-728) 310 (186-519)
Table 2.2 Gynecologic history and baseline sex hormones
Data presented as mean ± SE.  # Skewed variable, re-exponentiated to geometric mean and 95% 
confidence interval; *p<0.05 vs Caucasian; 
a
 n = 13 pooled, n = 7 Caucasian, n = 6 African American. HC, 
hormonal contraceptives; FSH, follicle-stimulating hormone; LH, luteinizing hormone. 
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Stage
Mean 
(µmol/l)
SEM 
(µmol/l)
Mean 
(µmol/l)
SEM 
(µmol/l)
Probe 1 n = 14 n = 16
1 Basal 35.5 3.5 39.0 3.6
2 Basal 30.4 2.4 35.9 2.4
3 Basal 30.5 2.5 30.4 2.2
4 Basal 30.2 1.8 28.4 1.7
5 Basal + EX 85.1 
a,b 7.8 57.4 
a 6.7
Probe 2 n = 14 n = 16
1 Basal 32.5 2.0 37.1 3.0
2 E2 31.3 
b 1.8 37.3 2.3
3 E2 27.3 2.4 31.9 
a 2.3
4 E2 28.2 2.2 30.3 2.1
5 E2 + EX 67.6 
a 6.0 56.8 
a 3.7
Probe 3 n = 15 n = 15
1 Basal 32.8 2.2 36.9 2.3
2 Basal 30.6 
b 1.4 37.0 2.6
3 ISO 106.6 
a,b 6.6 71.2 
a 3.6
4 ISO + PHEN 103.5 
b 6.8 71.7 3.1
5 ISO + PHEN + EX 158.0 
a,b 12.7 113.6 
a 6.8
Probe 4 n = 15 n = 15
1 Basal 40.2 4.5 37.8 2.3
2 E2 36.6 3.2 38.3 2.2
3 E2 + ISO 98.5 
a,b 7.8 78.2 
a 2.8
4 E2 + ISO + PHEN 93.2 
b 6.2 76.7 3.0
5 E2 + ISO + PHEN + EX 169.1 
a,b 10.0 103.9 
a 7.2
Data are from second timepoint in each stage.  Basal, control perfusion at rest;
ISO, isoproterenol; PHEN, phentolamine; EX, submaximal exercise.
a
 Different from previous stage within same probe (p < 0.05)
b
 Different from gluteal region within corresponding probe and stage (p ≤ 0.05)
Table 2.4  Dialysate glycerol concentrations measured by microdialysis in 
overweight-to-obese premenopausal women.
Abdominal Gluteal
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Stage Mean SEM Mean SEM
Probe 1 n = 14 n = 16
1 Basal 0.81 0.02 0.85 0.01
2 Basal 0.82 0.02 0.85 0.02
3 Basal 0.74 
a,b 0.02 0.83 0.02
4 Basal 0.79 
a 0.02 0.84 0.02
5 Basal + EX 0.77 
b 0.02 0.82 0.02
Probe 2 n = 14 n = 16
1 Basal 0.81 0.02 0.85 0.01
2 E2 0.76 0.03 0.83 0.02
3 E2 0.74 
b 0.02 0.82 0.02
4 E2 0.76 
b 0.03 0.83 0.01
5 E2 + EX 0.76 0.03 0.78 0.02
Probe 3 n = 15 n = 15
1 Basal 0.79
 b 0.02 0.85 0.02
2 Basal 0.80 
b 0.02 0.87 0.02
3 ISO 0.77 0.03 0.78 
a 0.02
4 ISO + PHEN 0.75 0.02 0.79 0.02
5 ISO + PHEN + EX 0.72 0.02 0.77 0.02
Probe 4 n = 15 n = 15
1 Basal 0.78 0.02 0.82 0.02
2 E2 0.80 0.02 0.78 0.02
3 E2 + ISO 0.75 
a 0.02 0.76 0.02
4 E2 + ISO + PHEN 0.81 
a 0.02 0.80 
a 0.01
5 E2 + ISO + PHEN + EX 0.75 
a 0.02 0.78 0.01
Data are from second timepoint in each stage.  Basal, control perfusion at rest;
ISO, isopreterenol; PHEN, phentolamine; EX, submaximal exercise.
a
 Different from previous stage within same probe (p < 0.05)
b
 Different from gluteal region within corresponding probe and stage (p < 0.05). 
Table 2.5  Ethanol outflow-to-inflow ratio (inversely related to blood 
flow) as measured by microdialysis in overweight-to-obese 
premenopausal women.
Abdominal Gluteal
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Baseline Pre-Exercise
Glucose, mmol/l (n=12) 4.5 ± 0.06 4.4 ± 0.07
Free Fatty Acids, uEq/l (n=10) 635 ± 44 765 ± 39
Glycerol, µmol/l (n=10) 116 ± 11 119 ± 9
Estradiol, pmol/l # (n=12) 221 (133-367) 234 (147-373)
Testosterone, nmol/l (n=12) 1.0 ± 0.16 1.20 ± 0.17*
Progesterone, nmol/l # (n=11) 0.37 (0.22-0.62) 0.46 (0.32-0.68)
Cortisol, nmol/l (n=12) 183 ± 11 216 ± 18
Epinephrine, pmol/l (n=7) < DL 172 ± 17
During-Ex
a
Post-Ex
b
Insulin, pmol/l (n=12) 43.1 ± 4.9 29.6 ± 4.0 29.3 ± 2.3 56.8 ± 9.0
†‡
Norepinephrine, nmol/l (n=10) 1.9 ± 0.21 1.9 ± 0.18 8.3 ± 1.2*
†
4.7 ± 0.4*
†‡
269 (163-443)
319 ± 43*
†
Table 2.7 Circulating humoral factors at rest and with submaximal aerobic exercise
Values are mean ± SE unless otherwise stated. *p<0.05 vs baseline, † p<0.05 vs pre-exercise, 
‡p<0.05 vs during-exercise.  # Skewed variable, presented as re-exponentiated to geometric mean and 
95% confidence interval.  
a
 n=7 for insulin, n=5 for norepinephrine. 
b
 n=5 for insulin and norepinephrine.  
DL, detection limit; Ex, exercise.
Exercise                                 
(Combined During and Post Ex)
4.9 ± 0.13*
†
940 ± 123*
487 ± 75
†
455 ± 59*
†
1.27 (0.75-2.14)*
†
1.53 ± 0.19*
†
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Figure 2.1. Microdialysis protocol. Four microdialysis probes were inserted in each the 
abdominal and gluteal subcutaneous adipose tissue undergoing identical treatments.  Probes were 
perfused with the following pharmacological agents: Control (0.9% sodium chloride with 
10mmol/l ethanol), isoproterenol (β-adrenergic agonist; 1.0 µmol/l), phentolamine (α-adrenergic 
antagonist; 0.1 mmol/l), and/or estradiol (500 nmol/l).  Ten microdialysis samples were collected 
at the minutes listed above and blood was drawn three times throughout visit (black arrows).  
REE was measured for 25 minutes at the start of Stage 2.  Stage 5 was 30 minutes of stationary 
cycle ergometry exercise at a previously determined 60% VO2peak.  BD, blood draw; REE, 
resting energy expenditure; Ex, exercise. 
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Figure 2.2.  Dialysate glycerol as measured by microdialysis in response to (A) exercise and (B) 
pharmacological modulation of lipolysis in abdominal and gluteal subcutaneous adipose tissue in 
overweight-to-obese premenopausal women.  Lipolysis was measured under control resting 
conditions or during physiological modulation by (A) 30 minutes of cycle ergometry exercise at 
60% of predetermined VO
2peak or pharmacologically by (B) 60 minutes of perfusion of 
isoproterenol (ISO; 1.0 µmol/l), 60 minutes of perfusion of ISO + phentolamine (PHEN; 
0.1mmol/l), and 30 minutes of ISO + PHEN + cycle ergometry exercise at 60% of predetermined 
VO
2peak.  Open circles with dotted lines (○), represent abdominal and open squares with dotted 
lines (□) represent gluteal adipose tissue.  All probes were perfused with a base control solution 
of 0.9% saline + 10 mmol/l ethanol.  Data are mean ± SE. (A) AB n = 14, GL n = 16; (B) AB n = 
15, GL n = 15. * p<0.05 abdominal vs gluteal, # p<0.05 vs previous timepoint in same region.  
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Figure 2.3.  Percent change in dialysate glycerol as measured by microdialysis at rest in 
abdominal (AB) and gluteal (GL) subcutaneous adipose tissue with-or-without perfusion of 
estradiol in overweight-to-obese premenopausal women. (A) Pooled population (AB, n=14; GL, 
n=16), (B) Caucasian women only (AB, n=7; GL, n=9), and (C) African American women only 
(AB, n=7; GL, n=7). Baseline is mean basal dialysate glycerol from min 15 and 30. Open 
symbols and dotted lines (○, □) represent the control perfused probes (0.9% saline + 10 mmol/l 
ethanol) and closed symbols and solid line (●, ■) represent the estradiol perfused probes (500 
nmol/l in 0.9% saline + 10 mmol/l ethanol).  Circles represent the abdominal region and squares 
represent the gluteal region.   
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Figure 2.4.  Effect of estradiol perfusion on the percent change in dialysate glycerol during 
exercise and pharmacological modulation as measured by microdialysis in the abdominal and 
gluteal subcutaneous adipose tissue of healthy overweight-to-obese premenopausal women.  
Percent change in dialysate glycerol was calculated: (A) from rest (basal) to after 30 minutes of 
submaximal cycle ergometry exercise (Ex, 60% VO2peak), (B) from basal to after 60 minutes of 
perfusion of isoproterenol (ISO, 1.0 µmol/l), (C) from the end of ISO alone to after 60 minutes 
of perfusion of ISO + phentolamine (PHEN, 0.1 mmol/l), and (D) from the end of ISO + PHEN 
to after 30 minutes of ISO + PHEN + Ex.  Dialysate glycerol was measured in all conditions (A-
D) with or without estradiol co-perfusion (500 nmol/l E2).  Data are mean ± SE.  Probe 1 & 2: 
abdominal, n=14; gluteal, n=16.  Probe 3 & 4: abdominal, n=15; gluteal, n=15. See Figure 2.1 
for details of study design containing key for probe numbers.  * p≤0.05 vs abdominal region of 
same probe; # p≤0.05 vs no-E2 probe in same region.  
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Figure 2.5.  Effect of estradiol perfusion on the percent change in ethanol outflow-to-inflow ratio 
during exercise and pharmacological modulation as measured by microdialysis in the abdominal 
and gluteal subcutaneous adipose tissue of healthy overweight-to-obese premenopausal women.  
Percent change in ethanol outflow-to-inflow ratio was calculated: (A) from rest (basal) to after 
30 minutes of submaximal cycle ergometry exercise (Ex, 60% VO2peak), (B) from basal to after 
60 minutes of perfusion of Isoproterenol (ISO, 1.0 µmol/l), (C) from the end of ISO alone to 
after 60 minutes of perfusion of ISO + Phentolamine (PHEN, 0.1 mmol/l), and (D) from the end 
of ISO + PHEN to after 30 minutes of ISO + PHEN + Ex.  All conditions (A-D) were conducted 
with or without estradiol co-perfusion (500 nmol/l E2).  Data are mean ± SE.  Probe 1 & 2: 
abdominal, n=14; gluteal, n=16.  Probe 3 & 4: abdominal, n=15; gluteal, n=15. See Figure 2.1 
for details of study design with key for probe numbers.  * p≤0.05 vs abdominal region of same 
probe; # p≤0.05 vs no-E2 probe in same region. 
  
 
 
CHAPTER 3: Estrogen Receptor Protein Content is Different in Abdominal than Gluteal 
Subcutaneous Adipose Tissue of Overweight-to-Obese Premenopausal Women 
  
Abstract 
Premenopausal women demonstrate a distinctive gynoid body fat distribution and 
circulating estrogen status is associated with the maintenance of this adiposity patterning.  
Estrogen’s role in modulation of regional adiposity may occur through estrogen receptors (ERs), 
which are present in human adipose tissue.  The purpose of this study was to determine if there 
are regional differences in the protein content of ERα, ERβ, and the G protein-coupled estrogen 
receptor (GPER) between the abdominal (AB) and gluteal (GL) SAT of overweight-to-obese 
premenopausal women.  A secondary aim was to determine if there are racial differences (CA vs 
AA) in regional ER protein content.  We found that ERα protein was higher in AB vs GL 
(p=0.02), ERβ protein was higher in GL vs AB (p=0.002), ERα/ERβ ratio was higher in AB vs 
GL (p=0.007), and GPER protein content was similar in AB and GL (p=0.80).  The regional 
content of ERβ and GPER was similar between CA and AA women, while ERα content was 
higher in AB vs GL SAT from CA (p=0.04) but not from AA women (p=0.17).  These results 
indicate that the effects of estrogen on abdominal and gluteal adiposity in premenopausal women 
may be regulated by the depot specific expression of estrogen receptors. 
 
Introduction 
 Premenopausal women demonstrate a distinctive gluteal-femoral body fat distribution (6, 
197, 198).  Although evolutionary reasoning behind this pattern of adiposity is not definitive one 
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hypothesis is that women accumulate energy reserves in the lower body in preparation for 
increased energy utilization and adipose mobilization from this depot during pregnancy and 
lactation (94, 99, 100).  Sequestration of fat in the lower body region is associated with 
decreased risk for cardiovascular and metabolic disease versus accumulation of central adiposity 
(5, 6, 16-19).  Therefore, a full understanding of the physiology behind why, and by what 
mechanisms, adipose accumulates in specific depots is important in efforts of obesity and 
chronic disease prevention. 
Estrogen status is related to the maintenance of a gynoid body fat distribution (36).  The 
loss of circulating estrogen over the menopause transition is associated with increases in central 
adiposity, a pattern of adiposity linked to increased cardio-metabolic disease risk (38-41).  The 
expression of estrogen receptor alpha (ERα) (119, 124), estrogen receptor beta (ERβ) (120-123), 
and the G protein-coupled estrogen receptor (GPER) (126) within human adipose tissue indicates 
estrogen has direct effects within adipose tissue (37).  Taken together, a shift toward increased 
central adiposity with decreases in circulating estrogen status and the presence of ERs within the 
adipose tissue present a strong case for modulation of adipose accumulation via estrogen, 
potentially in a region specific manner. 
There have been few investigations into regional differences in estrogen receptor 
expression in human adipose tissue, with most of those focusing on differences in estrogen 
receptor gene expression between subcutaneous and visceral abdominal adipose tissue. To our 
knowledge studies are lacking which characterize the protein content of all three estrogen 
receptors in upper and lower body adipose tissue in overweight or moderately obese women.  
There is limited evidence that ERβ mRNA expression is higher in gluteal than abdominal 
subcutaneous adipose tissue (SAT) from overweight premenopausal women (121), supporting 
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the hypothesis that regional differences in ER expression may be a mechanism behind regional 
differences in adipose accumulation and/or mobilization.  Importantly, ERα and ERβ are 
reported to have distinct actions and ERβ may even oppose the actions of ERα (121, 123, 137, 
230), highlighting the need for a clear representation of the relative ERα to ERβ ratio in each 
adipose depot.  
Therefore, the primary purpose of this study was to determine if there are regional 
differences in the protein content of ERα, ERβ, and GPER between the abdominal (AB) and 
gluteal (GL) SAT of overweight-to-obese premenopausal women demonstrating a gluteal-
femoral body fat distribution (defined as a waist-to-hip ratio < 0.85).  As a secondary aim, 
subgroup analyses investigated racial (Caucasian and African American) differences in regional 
ER protein content.  Establishing regional SAT ER protein content is an important step towards 
understanding how estrogen may affect adipose depots in the upper and lower body differently, 
potentially playing a modulatory role in regional adipose accumulation. 
 
Methods and Procedures 
Participants 
Fifteen overweight/obese premenopausal women, (7 Caucasian/8 African American, 
25.1±1.8 years, 81.3±2.5 kg, BMI 29.5±0.5 kg/m
2
) between 18 and 39 years old were studied.  
All but one participant also participated in the study from Chapter 2.  Participants enrolled in this 
study were eumenorrheic (average cycle length 30.5±1 days), not taking hormonal 
contraceptives (no use of hormonal contraceptives for at least 6 months at study entry), weight 
stable (< 3 kg weight change in the last 6 months) and sedentary, in that they did not engage in 
purposeful exercise training more than 30 minutes per day more than 2 days per week.  Women 
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were excluded from the study if they were trying to get pregnant, pregnant or lactating, a smoker, 
had history of diagnosis of any metabolic or cardiovascular disease, or were taking any 
medications known to alter lipid metabolism.  Qualification for the study was determined by a 
pre-participation health history questionnaire completed by the participant and reviewed for 
accuracy with study personnel.  All participants were informed both orally and in writing of the 
purpose, risks, and benefits of the research and provided informed consent prior to enrollment in 
the study.  This study was approved by the Medical Center Institutional Review Board at East 
Carolina University.  Participant characteristics are presented in Table 3.1.   
 
Body Composition 
Participants were weighed on an electronic scale with weight recorded to the nearest 0.1 
kg and height was measured with a standard stadiometer to the nearest centimeter (cm).  Minimal 
waist and hip circumferences were measured according to previously published guidelines and 
waist-to-hip ratio (WHR) was calculated (215).  Total percent body fat, fat-free mass (lean mass 
+ bone mineral content), and total and regional (android and gynoid) fat mass were determined 
using dual-energy x-ray absorptiometry (DXA; GE Lunar Prodigy Advance, Madison, WI).  
According to the manufacturer recommendations the android region was bound on the lower 
border by the top of the iliac crest and on the upper border at a distance 20% of the distance 
between the top of the iliac crest and immediately below the chin; lateral borders were the arm 
lines.  The gynoid region was bound on the upper border at a distance 1.5 times the height of the 
android region and on the lower border at a distance 2 times the height of the android region; 
lateral boundaries were the outer leg lines. 
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Adipose Tissue Biopsy 
Participants arrived at the East Carolina Diabetes and Obesity Institute (ECDOI) at the 
East Carolina Heart Institute between 7-8am after an overnight (≥10hr) fast during the follicular 
phase of the menstrual cycle (day 2-8 after the start of menses).  On average the biopsy visit 
occurred on day 5±2 of the cycle.  Approximately 1 gram of subcutaneous adipose tissue was 
removed using the needle aspiration technique (14 gauge needle) after local anesthesia by 
injection of 3-5cc of 1% lidocaine and under sterile conditions.  Biopsies were taken from the 
abdominal (AB), approximately 5cm lateral to the umbilicus, and the upper gluteal (GL) regions, 
approximately ~5-10 cm from the medial line in the upper quadrant of the buttock.  Fat tissue 
was immediately rinsed with Krebs Ringer Bicarbonate (KRB) buffer containing 1% bovine 
serum albumin (BSA).  Clots and blood vessels were then removed; tissue was immediately 
frozen in liquid nitrogen and stored at -80°C for later analysis. 
 
Western Blotting 
Adipose tissue samples were homogenized glass on glass in a 2:1 (volume-to-weight) 
ratio of cold homogenization buffer (50 mmol/l HEPES [pH 7.4], 1% SDS [sodium dodecyl 
sulfate], 2% Triton X-100, 2 mmol/l Ethylenediaminetetraacetic acid, 1 mmol/l sodium 
orthovanadate, 50 mmol/l sodium fluoride, 1 mmol/l benzamidine, 2 mmol/l dithiothreitol and 
protease inhibitor cocktail [Sigma P8340]).  Homogenized samples were rotated for 60 minutes 
and centrifuged for 30 minutes at 10,000 x g, both at 4°C.  The supernatant was then removed 
and protein concentration determined by the Pierce BCA protein assay (Thermo Scientific, 
Rockford, IL).  Samples were prepared in laemmli sample buffer (Bio-Rad, Hercules, CA) with 
5% β-mercaptoethanol and heated in a water bath at 90°C for 5 minutes.    
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Seventy micrograms of protein was loaded and separated on a 10% SDS-polyacrylamide 
gel (Criterion precast gels; Bio-Rad) and electrotransferred to reduced-fluorescence 
polyvinylidene difluoride membranes (Immobilon-FL; Millipore, Bedford, MA).   Membranes 
were blocked for 1 hour at room temperature with Odyssey Blocking Buffer (LI-COR 
Biosciences, Lincoln, NE) and then probed overnight at 4°C for ERα (1:400; sc-542; Santa Cruz 
Biotechnology, Santa Cruz, CA), ERβ (1:400; sc-8974; Santa Cruz Biotechnology) or GPER 
(1:300; sc-48524-R; Santa Cruz Biotechnology) and β-actin (1:2000; 926-42212; LI-COR).  
Primary antibodies were diluted in Odyssey blocking buffer containing 0.2% tween-20.  Blots 
were then washed with phosphate buffered saline containing 1% tween-20 (PBS-T) and 
incubated for 1 hour at room temperature in fluorescent secondary detection antibodies (IRDye 
800 CW-Donkey anti-Rabbit and IRDye 680LT Donkey anti-Mouse; LI-COR) diluted in 
Odyssey Blocking Buffer containing 0.2% tween-20 and 0.01% SDS. Fluorescence intensity data 
were quantified using the Odyssey infrared imaging system (LI-COR).  All samples were 
normalized to β-actin protein as well an internal control sample run on each gel and presented in 
arbitrary units.   
ERα and ERβ overexpression lysates (NBL1-10344 and NBL1-10345 respectively; 
Novus Biologicals, Littleton, CO), MCF 7 nuclear extract, and SKBR3 lysates (sc-2149, sc-
2218; Santa Cruz Biotechnology) were used as positive controls to confirm detection of proper 
molecular weight bands for ERα, ERβ and GPER respectively.  In addition, blocking peptides for 
ERα and GPER were utilized to further confirm proper band detection and quantification. 
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Blood Samples 
A fasting blood sample was drawn the morning of the microdialysis visit.  Fasting serum 
samples of glucose, total cholesterol (TC), triglycerides (TG), and high-density-lipoprotein 
(HDL) cholesterol were determined using enzymatic/colorimetric methods, and low-density-
lipoprotein (LDL) cholesterol was calculated using the Friedewald equation (222).  Homeostasis 
model assessment of insulin resistance (HOMA-IR) was calculated using the following equation 
[fasting glucose (mmol/l) x fasting insulin (µU/ml)]/22.5 (223). 
 
Statistics 
Independent sample t-tests were used to determine racial differences in subject 
characteristics.  Triglyceride was log transformed before analysis due to its skewed distribution.  
Paired t-tests were used to determine regional differences in estrogen receptor protein 
expression. Two-way repeated measure ANOVA (race x region) was used to determine racial 
differences (Caucasian versus African American) in estrogen receptor expression in the 
abdominal and gluteal SAT.  Pearson correlation coefficient was used to determine significant 
bivariate relationships between estrogen receptor expression and measurements of body 
composition.. 
 
Results 
Baseline characteristics of the participants in the study are included in Table 3.1.  African 
American women had elevated android fat mass compared to Caucasian women; all other 
participant characteristics were similar between the racial subgroups.   
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Figure 3.1A-C presents evidence of correct band detection for ERα, ERβ, and GPER.  
Positive control lysate samples and blocking peptides were utilized to confirm detection of the 
appropriate representative band for each protein of interest with the exception of ERβ (no 
blocking peptide available).  ERα was detected at a molecular weight just slightly below the 
expected 66 kDa, ERβ at the expected molecular weight of 56 kDa, and GPER at a molecular 
weight of approximately 40 kDa.   
 
ER Protein Content 
ERα protein content was higher in the abdominal compared to the gluteal SAT in the 
group as a whole (Figure 3.2a; p=0.02).  Sub-analyses for racial and regional differences in 
regional ERα protein revealed ERα protein content to be higher in the abdominal compared to 
gluteal in the Caucasian, but not the African American, women (Figure 3.2b; region x race p= 
0.04, main effect of race p=0.98, region p=0.008).  Low statistical power due to small sample 
sizes in the racial sub-analyses may limit our ability to detect significant differences within the 
racial subgroups.  
Conversely, ERβ protein content was significantly lower in abdominal versus gluteal 
SAT (Figure 3.3a; p=0.002) in this sample of overweight-to-obese premenopausal women.  
Abdominal and gluteal SAT from Caucasian and African American women expressed ERβ in 
similar patterns (Figure 3.3b; region x race p=0.405).  ERβ protein was significantly higher in 
the gluteal SAT compared to abdominal in both Caucasian (p=0.04) and African American 
women (p=0.02).   
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GPER protein content was not different between abdominal and gluteal SAT in the group 
as a whole (Figure 3.4a; p=0.53) or within racial sub-analyses (Figure 3.4b; Main effect of race 
p=0.31, region p=0.54).   
The ratio of ERα-to-ERβ protein was significantly higher in the abdominal compared to 
gluteal region (Figure 3.5a; p=0.007).  Racial analyses revealed a tendency for higher ERα/ERβ 
ratio in abdominal compared to gluteal SAT in both Caucasian (Figure 3.5b; p=0.064) and 
African American (p=0.064) subgroups (Main effect of region p=0.007, race p=0.71). 
 
Correlations 
 Correlation analyses were conducted to assess the relationship between ER protein 
content and anthropometric indices/body composition measurements and SAT estradiol 
concentrations.  WHR was inversely related to gluteal ERβ protein (r2=0.315, p=0.03) and 
positively related to gluteal ERα/ERβ ratio (r2= 0.406, p=0.01).  It is important to note that these 
correlations must be interpreted with caution due to lower statistical power resulting from a small 
sample size.   
 
Discussion 
 This is the first study to characterize protein content of the three known estrogen 
receptors, ERα, ERβ, and GPER, in abdominal and gluteal subcutaneous adipose tissue samples 
from Caucasian and African American premenopausal women.  Importantly, we found estrogen 
receptors had depot specific protein content pattern, in agreement with previously reported 
mRNA results (121).  Abdominal SAT contained more ERα protein compared to gluteal, and 
gluteal SAT contained more ERβ protein when compared to abdominal.  The resultant ERα-to-
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ERβ ratio was also higher in the abdominal versus gluteal depot.  We are the first to report GPER 
protein in human adipose tissue, to our knowledge only one previous study has measured GPER 
(mRNA) in human adipose tissue (126).  We found protein content of the membrane protein 
GPER to be similar between the two SAT depots.  Preliminary racial analyses revealed a similar 
ER distribution pattern for ERβ and GPER in the Caucasian and African American subgroups, 
but that Caucasian women have higher ERα in the abdominal versus gluteal while content of 
ERα was similar between the regions in the African American women.  Our results indicate that 
estrogen may have depot specific effects manifested in abdominal and gluteal differences in ERα 
and ERβ protein and the resultant ERα-to-ERβ ratio. 
 Only one previous study has investigated regional differences in ER expression in 
peripheral adipose depots, reporting only mRNA data.  Pedersen et al. found no difference in 
ERα mRNA expression between abdominal and gluteal SAT from overweight healthy 
premenopausal women, but did find ERβ isoforms ERβ-4 and ERβ-5 to be significantly higher in 
the gluteal versus abdominal SAT (121).  In the current study we also found ERβ protein content 
to be higher in gluteal that abdominal SAT.  It is important to note that our protein measurement 
did not distinguish between the multiple ERβ isoforms, but recognized a homologous sequence 
found in each of the ER isoforms.  In opposition to the findings of Pedersen et al. we did find 
ERα content to be higher in the abdominal compared to gluteal region, this could indicate a post-
translational modification occurring in ERα resulting in a regional difference in protein content, 
but not mRNA.    
 Investigations utilizing ER knockout models have allowed the determination of specific 
roles for ERα and ERβ in the maintenance of adipose tissue homeostasis.  Female ERα knockout 
(αERKO) mice demonstrate a marked increase in white adipose tissue compared to wild type 
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(133), implicating the E2/ERα signaling pathway in regulation of female white adipose tissue 
deposition.  In particular it seems that ERα, at least in the female mouse model, plays an 
inhibitory role in the development and total amount of white adipose tissue (133).  Conversely, 
female ERβ knockout (βERKO) mice do not demonstrate the obesity characteristics of ERα 
knockout models, while double ERα/ERβ knockout (DERKO) models express similar increases 
in body fat content to αERKO (134), reinforcing the importance of ERα.  A specific modulatory 
role for estrogen acting through the ERs has also been investigated utilizing reduction and 
repletion of circulating estrogen as induced by ovariectomy and estrogen replacement therapy in 
the three knockout models.  After ovariectomy, estrogen treatment reduces gonadal fat mass in 
wild type (WT) and βERKO but not αERKO or DERKO female mice, endorsing ERα’s role in 
reduction of fat mass (135) and confirming similar results found in previous investigations (133, 
136).  In addition, βERKO mice demonstrated an increased response to estrogen treatment 
(greater loss in fat mass) compared to wild type, indicating that ERβ may act as a repressor of, or 
in opposition to, the ERα mediated effects (127, 135).  From these knockout models ERα has 
been implicated as the primary ER in reduction of fat mass and ERβ may act to counteract or 
repress some of ERα’s effects in adipose tissue. 
Our results indicate the ERα/β ratio is higher in the abdominal versus gluteal region of 
overweight-to-obese premenopausal women.  These findings seem to be in agreement with the 
aforementioned results in which ERα confers the primary role of adiposity regulation (limiting 
adipose accumulation) and ERβ may repress the actions of ER. The lower ERα/ERβ ratio 
(increased ERβ effects/decreased ERα effects) we report in the gluteal SAT may provide a 
favorable environment for adipose accumulation and storage compared to the abdominal SAT.   
In support of this we found that WHR is inversely related to gluteal ERβ protein and directly 
 80 
 
related to gluteal ERα/ERβ ratio.  Our results indicate that depot specific effects of estrogen may 
be a result of divergent ER expression, which could in turn be a mechanism behind preferential 
gynoid adipose accumulation in premenopausal women.   
 GPER is the most recently discovered estrogen receptor and its role in adipose tissue 
remains uncertain.  This is only the second study conducted in human adipose tissue to confirm 
the presence of GPER, and the first to detect GPER protein.  The similarity between GPER 
protein in the abdominal and gluteal SAT leads us to believe that this membrane associated ER is 
not a primary pathway through which estrogen has its effects on region specific adiposity in 
premenopausal women.  However, this does not exclude GPER from potentially playing an 
important role in estrogen mediated effects on lipid metabolism within the adipose tissue.  We 
did find a direct relationship between dialysate and interstitial E2 and GPER protein content in 
the gluteal depot, providing evidence that local estrogen concentration may be involved in 
determining depot GPER content.  Consistent with similar regional protein content of GPER, we 
did not find a regional difference in SAT E2 concentration, but as adipose tissue becomes the 
primary source of estrogen after menopause, depot specific changes in the local E2 concentration 
may result in altered regional expression in GPER (and ERα and ERβ) and reveal a region 
specific role for GPER in shifts in body fat distribution with menopause.  However, future 
studies are needed to clarify the specific role of GPER in adipose tissue metabolism and the 
influence of local E2 concentration on its expression. 
 Our small sample size and homogenous population may have limited our ability to detect 
racial differences in ER expression as part of the current study.  Our findings of similar ERβ, and 
GPER protein content between our subgroups of CA and AA women does not rule out a 
potential role for estrogen to mediate some of the reported differences in subcutaneous and 
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visceral adipose tissue accumulation (22-24) and disease risk demonstrated between these groups 
(27, 231, 232).  In fact, our preliminary finding that ERα content was higher in abdominal 
compared to gluteal SAT in Caucasian women but not African American women supports that 
possibility.  Future studies investigating racial differences in ER protein, particularly differences 
between subcutaneous and visceral adipose tissue, are warranted  
The associative nature of this study does not allow for direct cause and effect conclusions 
to be drawn about estrogen action through estrogen receptors in adipose tissue.  It was not our 
intention to investigate regional differences in the signaling cascades resulting from estrogen 
activation of each of the three ERs.  Nevertheless, we do provide strong preliminary evidence for 
region specific effects of estrogen to be mediated at least in part by differences in ER content.  
Comparisons of region specific protein content of ERα, ERβ, and GPER in premenopausal and 
postmenopausal women demonstrating clear upper and lower body fat distributions are needed 
for further confirmation of the association between regional ER expression regional adiposity.  
Furthermore, mechanistic studies clarifying intracellular signaling cascades resulting from 
activation of each of the estrogen receptors and their influence on adipose tissue metabolism are 
of great interest in further understanding region specific effects of estrogens on regional 
adiposity through ER signaling. 
 
Conclusions 
 The novel results from the current study demonstrate clear differences in ERα and ERβ 
protein content in the abdominal and gluteal SAT of overweight-to-obese premenopausal 
women.  The presence of all three ER subtypes in SAT as well as increased ERα expression in 
the abdominal, and increased ERβ expression in the gluteal, SAT suggests that ERα and ERβ 
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may both play a role in modulating regional adiposity.  Furthermore, these results support the 
hypothesis that ERβ may counteract ERα mediated actions to decrease adipose accumulation, 
resulting in a favorable environment for adipose accumulation in the gluteal region of 
premenopausal women.  Finally, we demonstrated well matched premenopausal Caucasian and 
African American women have similar regional expression ERβ and GPER, but that there may 
be a racial difference in regional expression of ERα.  These results indicate that the effects of 
estrogen on adipose tissue metabolism in premenopausal women may depend on the depot 
specific protein content of the ERs, and more specifically the local ratio between ERα and ERβ. 
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Variable Pooled Caucasian African American
n 15 7 8
Age, yrs 25.1 ± 1.8 25.0 ± 2.7 25.1 ± 2.6
Weight, kg 81.3 ± 2.5 78.6 ± 1.5 83.8 ± 4.5
BMI, kg/m
2
29.5 ± 0.6 28.4 ± 0.3 30.5 ± 0.9
Waist Circumference, cm 88.4 ± 1.3 87.6 ± 1.5 89.2 ± 2.0
WHR 0.79 ± 0.01 0.79 ± 0.02 0.79 ± 0.02
Body fat, % 44.3 ± 1.2 43.7 ± 0.8 44.8 ± 2.2
Android Fat Mass, kg 3.1 ± 0.2 2.7 ± 0.2 3.4 ± 0.2*
Gynoid Fat Mass, kg 7.0 ± 0.2 6.9 ± 0.3 7.1 ± 0.3
Total Cholesterol, mmol/l 3.9 ± 0.2 3.8 ± 0.2 3.9 ± 0.3
HDL Cholesterol, mmol/l 1.2 ± 0.1 1.2 ± 0.1 1.2 ± 0.1
LDL Cholesterol, mmol/l 2.3 ± 0.1 2.2 ± 0.2 2.4 ± 0.2
Triglycerides, mmol/l # 0.72 (0.53-0.98) 0.78 (0.49-1.27) 0.66 (0.43-1.02)
Fasting Glucose, mmol/l 4.8 ± 0.1 4.8 ± 0.1 4.8 ± 0.1
Fasting Insulin, pmol/l 58.4 ± 6.2 62.3 ± 8.2 54.5±9.8
HOMA-IR 1.7 ± 0.2 1.9 ± 0.2 1.6 ± 0.3
Data are mean ± SE unless otherwise indicated. * p<0.05 vs Caucasian; # Skewed variable, 
re-exponentiated to geometric mean and 95% confidence interval.  BMI, body mass index; 
WHR, waist-to-hip ratio; HDL, high density lipoprotein; LDL, low density lipoprotein, 
HOMA-IR, homeostasis model assessment of insulin resistance.
Table 3.1.  Participant characteristics
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Figure 3.1.  Western blotting of ERα, ERβ, and GPER from human subcutaneous adipose tissue 
(SAT). (a)  ERα. Lane 1: 10µg ERα lysate, 2: 25µg MCF7 Nuclear Extract, 3: 40µg Human SAT, 
4: 60µg Human SAT. (b) ERβ. Lane 1: 20µg ERβ lysate, 2: 25µg MCF7 Nuclear Extract, 3: 
Empty well – loading buffer only, 4: 20µg Human SAT, 5: 40µg Human SAT, 6: 60µg Human 
SAT.  (c) GPER. Top panel, Lane 1: 20µg SKBR3 lysate, Lanes 2-5: 70µg Human SAT.  Bottom 
panel, identical to top panel with blocking peptide (BP) added to immunize GPER primary 
antibody. 
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Figure 3.2.  Estrogen receptor (ER) α protein content in abdominal and gluteal subcutaneous 
adipose tissue of overweight-to-obese premenopausal women.  (a) Pooled group, n=15.  (b) 
Caucasian (n=7) and African American (n=8) subgroups.  Main effect of region p=0.08.  (c) 
Representative western blot for ERα and β-actin.  Data are normalized for β-actin and internal 
control sample and presented as mean ± SE.  AB, abdominal; GL, gluteal.   
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Figure 3.3.  Estrogen receptor (ER) β protein content in abdominal and gluteal subcutaneous 
adipose tissue of overweight-to-obese premenopausal women.  (a) Pooled group, * p<0.05 versus 
abdominal region.  n=15.  (b) Caucasian (n=7) and African American (n=8) subgroups.  Main 
effect of region p=0.002.  * p<0.05 vs abdominal region of same race.  (c) Representative 
western blot for ERβ and β-actin.  Data are normalized for β-actin and internal control sample 
and presented as mean ± SE.  AB, abdominal; GL, gluteal. 
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 Figure 3.4.  G protein-coupled estrogen receptor (GPER) protein content in abdominal and 
gluteal subcutaneous adipose tissue of overweight-to-obese premenopausal women.  (a) Pooled 
group, n=15.  (b) Caucasian (n=7) and African American (n=8) subgroups.  (c) Representative 
western blot for GPER and β-actin.  Data are normalized for β-actin and internal control sample 
and presented as mean ± SE.  AB, abdominal; GL, gluteal.  
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Figure 3.5.  Ratio of ERα-to-ERβ protein in abdominal and gluteal subcutaneous adipose tissue 
in overweight-to-obese premenopausal women. (a) Pooled group, * p<0.05 vs abdominal region, 
n=15. (b) Caucasian (n=8) and African American (n=8) subgroups.  Main effect of region 
p=0.007.  Data are mean ± SE. 
 
  
  
 
 
CHAPTER 4:  Abdominal and Gluteal Adipocyte Diameter Distributions are Different in 
Overweight-to-Obese Caucasian and African American Premenopausal Women 
 
Abstract 
Regional adiposity is associated with disease risk, but this relationship is divergent by 
race.  African American women (AA) have more cardiovascular disease risk factors and a higher 
incidence of Type 2 diabetes and hypertension than Caucasian women (CA) despite 
accumulating less visceral fat, for a given BMI.  The primary purpose of this study was to 
determine if there are differences in adipocyte size populations (tertiles: small 25-83µm, medium 
84-142µm, and large 143-200µm) in subcutaneous adipose tissue (SAT) from the abdominal 
(AB) and gluteal (GL) regions of overweight-to-obese premenopausal women, and if these 
regional adipocyte size distributions differ between CA and AA women.  There was a trend for 
an interaction between region and race for mean adipocyte size (CA: AB 0.49±0.04 µg lipid/cell, 
GL 0.53±0.03 µg lipid/cell; AA: AB 0.59±0.06 µg lipid/cell, GL 0.47±0.04 µg lipid/cell; region 
x race, p=0.08).  CA women had a higher percentage of medium adipocytes in both the AB 
(51±3% vs 43±3%; p=0.046) and GL regions (50±4% vs 37±4%; p=0.02) compared to AA 
women.  AA women had a higher percentage of small adipocytes in the GL region compared to 
CA (55±4% vs 44±3%; p=0.044) and a trend for a higher percentage of large adipocytes in the 
AB region (13±2% vs 7±2%; p=0.065).  In light of previous evidence indicating that both small 
and large adipocytes have been associated with unfavorable metabolic indices, we provide 
preliminary evidence from a small sample of women in support of the hypothesis that racial 
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divergence in adiposity related disease risk may be associated with the morphological differences 
in AB and GL SAT adipocyte size between CA and AA women.  
 
Introduction 
Subcutaneous adipose tissue (SAT) serves as the body’s major energy storage depot.  The 
size of the SAT depot is in constant flux, with weight gain leading to increases in adipocyte size 
(hypertrophy) and in some cases adipocyte number (hyperplasia) (233-235).  Although not a new 
concept, the significance of upper versus lower body obesity has recently come to the forefront 
when trying to understand the health risks associated with increasing adiposity (7-9).  People 
carrying excess adipose in their abdominal region, either subcutaneously or viscerally, tend to 
have increased risk of cardiovascular disease, diabetes and the Metabolic Syndrome compared to 
someone of a similar BMI or weight who has increased lower body adiposity (7, 10-13).  Some 
studies have even found gynoid adiposity has a protective effect on disease risk (5, 6, 16-18). 
Accumulating adiposity in the subcutaneous depot may not be as benign or favorable as 
previously believed, at least in regards to people of certain ethnicities.  For a given BMI, African 
American (AA) women tend to accumulate more adipose subcutaneously than viscerally, but 
have a higher incidence of Type 2 diabetes and hypertension than Caucasian (CA) women (22-
24, 28).  Further, the relationship between central fat deposition and metabolic risk factors is 
weaker in African Americans in comparison to Caucasians (23), resulting in a racially divergent 
association between regional adiposity and disease risk.  Inherent phenotypic and morphologic 
differences in the SAT depots between CA and AA women are likely to be involved in the 
apparent conflicting role of SAT adiposity in these groups.  An elevated inflammatory profile 
(236) and increased adipocyte insulin resistance in SAT from black compared to white women 
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(85, 237) are two potential mechanisms behind the negative health outcomes associated with 
increased SAT in African American women.   
 Measurements of adipocyte size are commonly used to investigate depot specific 
differences in adipose tissue characteristics.  These studies have established that abdominal 
subcutaneous adipocyte size is positively associated with unfavorable metabolic indices in both 
men and women independent of obesity and visceral adiposity (206, 238), while femoral 
adipocyte size displays a weaker association or no association at all (239).   
Recent advances in adipocyte sizing techniques have resulted in the more common use of 
size distributions as opposed to mean cell size, revealing the complexities of adipocyte size (202, 
203, 240, 241).  Use of these new techniques have a revealed a role for small adipocytes in 
increased disease risk factors associated with adiposity, such as insulin resistance and 
inflammation (202, 203).  As such, the use of adipocyte size distributions to determine the 
proportion of large and small adipocytes in adipose tissue depots is an important tool in 
establishing morphological differences between adipose tissue depots and between populations 
of varying disease risk.  Therefore the primary purpose of this study was to determine if there are 
differences in adipocyte size populations in SAT from the abdominal and gluteal regions of 
overweight-to-obese premenopausal women.  A secondary aim was to determine if there are 
differences in regional adipocyte size distributions between well matched subgroups of 
Caucasian and African American premenopausal women. 
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Methods and Procedures 
Participants 
Seventeen overweight-to-obese premenopausal women, (8 Caucasian/9 African 
American, 25.9±1.7 years, 81.4±2.3 kg, BMI 29.5±0.5 kg/m
2
) between 18 and 39 years old were 
studied.  All but one participant also participated in the studies from Chapters 2 and 3. Enrolled 
participants were eumenorrheic (average cycle length 30.5±1 days), not taking hormonal 
contraceptives (no use of hormonal contraceptives for at least 6 months at study entry), weight 
stable (< 3 kg weight change in the last 6 months) and sedentary, in that they did not engage in 
purposeful exercise training more than 30 minutes per day more than 2 days per week.  Women 
were excluded from the study if they were pregnant or lactating, a smoker, had history of 
diagnosis of any metabolic or cardiovascular disease, or were taking any medications known to 
alter lipid metabolism.  Qualification for the study was determined by a pre-participation health 
history questionnaire completed by the participant and reviewed for accuracy with study 
personnel.  All participants were informed both orally and in writing of the purpose, risks, and 
benefits of the research and provided informed consent prior to enrollment in the study.  This 
study was approved by the Medical Center Institutional Review Board at East Carolina 
University.  Participant characteristics are presented in Table 4.1.   
 
Body Composition 
Participants were weighed on an electronic scale with weight recorded to the nearest 0.1 
kg and height was measured with a standard stadiometer to the nearest centimeter (cm).  Minimal 
waist and hip circumferences were measured according to previously published guidelines and 
waist-to-hip ratio (WHR) was calculated (215).  Total and regional fat mass (android, gynoid), 
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fat-free mass (lean mass + bone mineral content), and total percent body fat were determined 
using dual-energy x-ray absorptiometry (DXA; GE Lunar Prodigy Advance, Madison, WI).  
According to the manufacturer recommendations the android region was bound on the lower 
border by the top of the iliac crest and on the upper border at a distance 20% of the distance 
between the top of the iliac crest and immediately below the chin; lateral borders were the arm 
lines.  The gynoid region was bound on the upper border at a distance 1.5 times the height of the 
android region and on the lower border at a distance 2 times the height of the android region; 
lateral boundaries were the outer leg lines. 
 
Blood samples 
Blood was drawn in the morning after an overnight fast (≥ 10 hours) the morning of the 
day immediately before or after the biopsy visit (baseline blood draw from microdialysis visit in 
Study 1/Chapter 2).  Fasting serum samples of glucose, total cholesterol (TC), triglycerides (TG), 
and high-density-lipoprotein (HDL) cholesterol were determined using enzymatic/colorimetric 
methods, and low-density-lipoprotein (LDL) cholesterol was calculated using the Friedewald 
equation (222).  Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated 
using the following equation [fasting glucose (mmol/l) x fasting insulin (µU/ml)]/22.5 (223).  
Serum free fatty acid (FFA) measurements were determined by enzymatic colorimetric methods 
(Wako Diagnostics USA, Richmond, VA; Intra-assay CV 1.1%, Inter-assay CV 5.6%)   
performed by the University of Colorado Denver Clinical and Translational Research Center 
(CTRC) Core laboratory. 
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Adipose Tissue Biopsy 
Participants arrived at the East Carolina Diabetes and Obesity Institute (ECDOI) at the 
East Carolina Heart Institute between 7-8am after an overnight (≥10hr) fast during the follicular 
phase of the menstrual cycle (day 2-8 after the start of menses).  On average the biopsy visit 
occurred on day 5±2 of the cycle.  Approximately 1 gram of subcutaneous adipose tissue was 
removed using the needle aspiration technique (14 gauge needle) after local anesthesia by 
injection of 3-5cc of 1% lidocaine and under sterile conditions.  Biopsies were taken from the 
abdominal (AB), approximately 5cm lateral to the umbilicus, and the upper gluteal (GL) regions, 
approximately ~5-10 cm from the medial line in the upper quadrant of the buttock.  Processing 
and cell sizing were conducted according to previously published methods (242) with 
modifications.  Fat tissue was immediately rinsed with Krebs Ringer Bicarbonate (KRB) buffer 
containing 1% bovine serum albumin (BSA) on top of a 70µm cell strainer, clots and blood 
vessels were then removed.  At least 300 milligrams of adipose tissue were transferred into fresh 
KRB buffer on ice and minced for 10 minutes.  Collagenase Type 1 (CLS1 - Worthington 
Biochemical), 2 mg/mL, was added to the minced tissue and the sample was incubated for 30-60 
minutes in a 37°C water bath (100 shakes/min).  After collagenase digestion the floating 
adipocyte layer was washed two times with fresh KRB buffer and stained with 0.1% methylene 
blue.  After five minutes, 200µl of the floating adipocyte layer was pipetted onto a glass slide 
and photographs of the cell suspension at 100x magnification were captured optically using a 
microscope at phase contrast with digital photography capability (Nikon Eclipse TS100; Nikon 
Inc, Melville, NY).  Digital photographs containing ≥ 250 adipocytes were saved for subsequent 
analyses.   
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 The diameter of 250 adipocytes was determined using the US National Institutes of 
Health (NIH) ImageJ software program (243).  The scale was set using a digital photograph of a 
1mm stage micrometer taken immediately preceding the adipocyte images for each participant.  
Twenty-five µm was set as the lower limit for adipocyte size (244).  Frequency distributions with 
10µm diameter bins were generated for each participant generating a relative frequency 
distribution for each biopsy sample.  Tertiles for adipocyte size were also calculated resulting in 
sub-groups of small (25-83 µm), medium (84-142 µm), and large (143-200 µm) diameters.  
Adipocyte size (mean adipocyte weight; µg lipid/cell) was calculated according to Hirsch and 
Gallian (245) using the formula: 
 
where d = mean diameter and σ = standard deviation and assuming that each cell is a sphere 
composed of material with the density of triolein (0.915 g/ml).  For each adipose sample, 
adipocyte size (adipocyte weight) was calculated using the mean diameter and standard deviation 
for that individual sample, a mean value for each racial subgroup and region was calculated and 
is presented in Table 4.2. 
 
Statistics 
Group differences in subject characteristics were determined using two sample 
independent sample t-tests.  Two-way analysis of variance (ANOVA) (2 x 2; race x region) was 
used to determine race and regional differences in mean adipocyte diameter and size.  Two-way 
ANOVAs (2 x 3) were also used to determine regional (region x adipocyte size subgroup) and 
racial (race x adipocyte size subgroup) differences in adipocyte size distribution in each the 
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abdominal and gluteal regions.  When indicated by a significant F statistic post hoc analyses 
were conducted with the bonferroni correction.  Pearson correlation coefficient was used to 
determine significant bivariate relationships between mean adipocyte size and baseline 
circulating characteristics and body composition measurements.  The small sample size of the 
current study limits the statistical power; therefore all analyses should be interpreted with caution 
and considered preliminary evidence in support of conducting larger investigations in this area in 
the future. 
  
Results 
Participant Characteristics 
Seventeen overweight-to-obese premenopausal women took part in the study; there were 
no mean differences in any baseline participant characteristics between the Caucasian and 
African American women including BMI, WHR, and total percent body fat.  Participant 
characteristics can be found in Table 4.1.    
 
Mean Adipocyte Diameter and Adipocyte Size  
 Representative adipocyte photographs used for sizing analyses can be found in Figure 
4.1.  There were no mean differences in adipocyte diameter by region or race in abdominal and 
gluteal adipocytes of Caucasian and African American women.  Similar results were found when 
analyses were conducted after calculation of adipocyte size (µg lipid/cell) although there was a 
tendency for a significant interaction between region and race (p=0.08) when data were 
expressed in this manner.  Mean diameter and adipocyte size results can be found in Table 4.2.   
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Adipocyte Diameter Distribution 
Pooled group of all participants.  Frequency distribution of adipocyte diameters in the 
abdominal and gluteal regions in the pooled group can be found in Figure 4.2A.  Tertile sub-
population analyses revealed a significantly smaller proportion of large diameter adipocytes 
compared to small and medium diameter adipocytes (Figure 4.2B; main effect of size p<0.001).  
Percentage of adipocytes falling into the small, medium, and large diameter subgroups was 
similar between the abdominal and gluteal regions (main effect of region p=0.33, interaction size 
x region p=0.15). 
Racial analyses.  Racial comparison of adipocyte diameter frequency distributions from 
abdominal and gluteal SAT can be found in Figure 4.3.  Diameter subgroup comparisons 
between Caucasian and African American women revealed differences in adipocyte diameter 
distributions between the races in both the abdominal and gluteal regions.  In the abdominal 
region there was a trend for an interaction between adipocyte size and race (Figure 4.4A, size x 
race p=0.064, main effect of size p<0.0001, race p=0.01).  AA women had a lower proportion of 
adipocytes in the medium diameter category (p=0.046), and tended to have a greater percentage 
of adipocytes in the large diameter group (p=0.065) compared to CA women.  In the gluteal 
region, there was a significant interaction between size and race (Figure 4B, size x race p=0.008) 
with AA women having a higher percentage of adipocytes in the small category (p=0.037), and a 
lower percentage of adipocytes in the medium diameter group (p=0.02) compared to the CA 
women. 
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Correlations 
 Correlation analyses were conducted to assess the relationship between regional 
adipocyte size and anthropometric indices/body composition measurements and baseline 
circulating factors.  Abdominal cell size was directly related to DXA weight (r
2
 = 0.45), BMI (r
2
 
= 0.45), total body fat mass (r
2
 = 0.27), and waist circumference (r
2
 = 0.32) (all p<0.05).  Gluteal 
cell size was negatively related to plasma FFA (r
2 
= 0.40, power=0.82), a relationship primarily 
driven by the AA women.  When separated by race, gluteal adipocyte size in AA women 
maintained a significant inverse correlation with FFA (r
2
 = 0.73, p=0.007) while CA women did 
not (r
2
 = 0.15, p=0.35).  Correlation analyses must be interpreted with caution due to the limited 
sample size; however statistical power was greater than 0.80 for all correlations with exception 
of the relationships between abdominal cell size and total body fat mass as well as abdominal 
cell size and waist circumference.  
 
Discussion 
 This is the first investigation of adipocyte diameter distribution in abdominal and gluteal 
subcutaneous adipose tissue from overweight/obese premenopausal Caucasian and African 
American women.  The novel finding of this study was that, even when matched for BMI and 
WHR, the African American women had a higher proportion of small adipocytes (25-83 µm) in 
the gluteal SAT, and a trend for a higher proportion of large fat cells (143-200 µm) in the 
abdominal SAT, than the Caucasian women.  Conversely, the Caucasian women had an 
increased proportion of medium sized adipocytes (84-142 µm) in both the abdominal and gluteal 
SAT compared to the African American women.  Increased numbers of both large and small 
adipocytes can be indicative of an elevated metabolic risk profile (202, 203, 246-250).  These 
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results emphasize the importance of analyzing not only mean adipocyte diameter when 
characterizing an adipose sample, but investigating the entire adipocyte diameter distribution.  
Future investigations on larger samples of Caucasian and African American women are 
warranted to confirm these preliminary findings and gain a better understanding of their 
physiological importance. 
Analyses conducted on mean adipocyte size, the calculation of which takes into account 
the standard deviation of the mean adipocyte diameter (and therefore the large variation of the 
data), did show a trend for divergent mean abdominal and gluteal adipocyte size between the CA 
and AA groups; gluteal adipocytes tended to be larger in Caucasian women and abdominal 
adipocytes tended to be larger in African American women.  Although this finding supports that 
mean adipocyte size can detect the racial regional differences in studies with sufficient sample 
size, the mean measurement lacks the detail of a size distribution for reporting distinct 
morphological differences between the groups, particularly with respect to the large and small 
adipocyte subgroups.   
 African American, in comparison to Caucasian, women have less visceral fat for a similar 
BMI, waist circumference, or waist-to-hip ratio (22-24).  Visceral adipose tissue (VAT) volume 
is generally the depot implicated in increasing disease risk.  However, AA have more 
cardiovascular disease risk factors (27) and a higher incidence of Type 2 diabetes and 
hypertension than CA women (28) even at the same BMI, despite the fact that more of their 
adipose accumulation occurs in the subcutaneous depots.  This relationship between SAT/VAT 
and disease risk in AA women represents an inconsistency between traditional beliefs about 
regional adiposity and disease.  The importance of excess abdominal SAT should not be 
overlooked, particularly in regards to increased insulin resistance risk (29, 30), a point that seems 
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to be of particular significance in overweight and obese African American women.   Insulin 
sensitivity in black women is most closely associated with the subcutaneous abdominal adipose 
tissue while in white women the association with insulin sensitivity is equal between visceral and 
abdominal subcutaneous depots (31, 32).  This divergent association between subcutaneous 
adipose tissue and disease risk between Caucasian and African American women at a given BMI 
may be related to our finding that women from these racial groups demonstrate different SAT 
adipocyte diameter distributions. 
Maintenance of a healthy or “normal” adipocyte size, as opposed to excessive adipocyte 
hypertrophy, in SAT may help preserve a less negative association of SAT with insulin 
resistance and cardiometabolic disease risk factors.  An increased proportion of medium sized 
adipocytes, representing the most benign subgroup of adipocyte, in Caucasian women may be 
linked to the reduced disease risk associated with SAT, compared to VAT, accumulation in 
Caucasian women for a given total adiposity.  These normal medium size adipocytes are likely 
insulin sensitive and able to rapidly respond to metabolic demands for storage or mobilization of 
lipids throughout the day.  In contrast, large, or hypertrophied, adipocytes, which tend to be in 
higher proportion in the AA women, are associated with insulin resistance (205, 246, 248), 
increased lipolytic rate (97, 204, 251), increased secretion of inflammatory adipokines (249, 
250), as well as local adipose tissue macrophage infiltration (252, 253), and even increased cell 
death (252), all characteristics that may be associated with negative metabolic outcomes.  We 
found abdominal adipocyte size was directly associated with DXA weight, BMI, fat mass, and 
waist circumference in our women, in support of previous evidence relating increased abdominal 
adipocyte size to increased cardiometabolic disease risk factors (205, 249, 250).  Therefore, an 
abdominal adipose tissue depot displaying a high proportion of large diameter adipocytes, such 
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as abdominal SAT of AA women in the current study, would be more likely to be insulin 
resistant and/or metabolically dysfunctional compared to the abdominal SAT of CA women, 
which displays a higher proportion of medium diameter adipocytes. 
 In the gluteal region we found AA women had an increased relative percentage of small 
adipocytes compared to CA women.  Contrary to more classical evidence discussed above, a 
recent study investigating overweight-to-obese insulin sensitive and insulin resistant, primarily 
Caucasian, adults found a predominance of small adipose cells in the insulin resistant group 
while unexpectedly finding no difference in the size of the large adipocytes between the groups 
(202).  In a subsequent study McLaughlin et al. further established that an increased proportion 
of small (versus large) adipose cells independently predicted expression of inflammatory genes 
in moderately obese, again primarily Caucasian, adults (203), reemphasizing the importance of 
cell size on health risk factors.  It is possible that the accumulation of small adipocytes in the 
gluteal region of AA results from an increased need to store triacylglycerol (TAG) despite the 
inability of the adipocyte to further progress in TAG storage (202).  Impaired fat storage capacity 
or differentiation of small adipocytes may be related to the increased inflammatory profile of 
small cells (203) and/or the decreased exposure to local adipokines which are secreted from full 
size (medium size) adipocytes (250), of which there is a reduced proportion in our subgroup of 
AA women.  Interestingly, we found gluteal adipocyte size to be negatively associated with 
plasma FFA levels, a relationship that was primarily driven by the AA women.  Elevated 
circulating FFAs are related to impaired vascular function, insulin resistance, and elevated risk of 
Type 2 diabetes (254, 255).  Therefore, the increased proportion of small adipocytes in the 
gluteal region of AA women may be associated with the negative health outcomes apparent in 
AA compared to CA women of similar obesity status.   
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 There are limitations to the current study, the first of which is that we only characterized 
adipocyte diameter and size.  No mechanistic or cause-and-effect conclusions can be drawn at 
this time.  Although supporting evidence exists, more research needs to be conducted on the 
phenotypic and biochemical differences between small, medium, and large adipocytes in 
Caucasian and African American women in determining their relationship with regional 
adiposity associated disease risk.  This study had a small sample size and narrow BMI range, 
limiting the applicability of our results solely to overweight-to-obese premenopausal women.  
However, the average BMI of our groups (Caucasian = 28.8 kg/m
2
, African American = 30.2 
kg/m
2
) were similar to that of the current mean age adjusted BMI for women over the age of 20 
in the United States, which is 28.7 kg/m
2
 (20), indicating our study sample was a good 
representation of typical American women.   
 
Conclusions 
African American women demonstrated an increased proportion of small adipocytes in 
the gluteal region and a trend for an increased proportion of large adipocytes in the abdominal 
SAT compared to Caucasian women, who had increased proportions of medium sized adipocytes 
in both regions.  Both large and small adipocytes have been associated with increased insulin 
resistance and inflammatory markers in previous investigations.  This racial divergence in SAT 
adipocyte morphology may be an underlying contributing factor in the increased CVD risk 
factors and diabetes incidence in AA compared to CA of the same BMI.  Although for 
investigations with a large sample size mean adipocyte size measurements may be indicative of 
general racial differences in regional adipocyte morphology, we conclude that characterizations 
of adipocyte diameter distributions are necessary to fully define the local adipose tissue depot 
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with respect to small, medium, and large adipocytes.  Larger scale studies are needed to confirm 
these racial differences in adipocyte size distribution and further characterize differences in 
adipocyte size and its association with cardiometabolic disease risk. 
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Variable Pooled Caucasian African American
n 17 8 9
Age, yrs 25.9±1.7 25.1±2.3 26.6±2.7
Weight, kg 81.4±2.3 79.9±1.9 82.8±4.1
BMI, kg/m
2
29.5±0.5 28.8±0.4 30.2±0.8
Waist Circumference, cm 88.5±1.1 87.7±1.3 89.3±1.8
WHR 0.79±0.01 0.78±0.02 0.79±0.01
Body fat, % 44.9±1.1 44.2±0.9 45.6±2.0
Total Body Fat Mass, kg 36.8±1.6 35.4±1.5 38.0±2.8
Android Fat Mass, kg 3.0±0.2 3.1±0.2 2.9±0.3
Gynoid Fat Mass, kg 7.0±0.3 7.0±0.3 7.0±0.4
Total Cholesterol, mmol/l 3.9±0.2 3.8±0.2 4.0±0.2
HDL Cholesterol, mmol/l 1.3±0.1 1.3±0.1 1.2±0.1
LDL Cholesterol, mmol/l 2.2±0.2 2.1±0.2 2.4±0.1
Triglycerides, mmol/l # 0.73 (0.56-0.95) 0.79 (0.49-1.27) 0.67 (0.47-0.96)
Free Fatty Acids, uEq/l (n=10) 576 ± 35 541 ± 51 611 ± 47
Fasting Glucose, mmol/l 4.8±0.1 4.8±0.1 4.7±0.1
Fasting Insulin, pmol/l 55.3±5.9 59.8±7.5 50.8±9.3
HOMA-IR 1.7±0.2 1.8±0.2 1.5±0.3
Table 4.1  Participant characteristics
Data are presented as mean±SE unless otherwise indicated.  # Skewed variable, re-
exponentiated to geometric mean and 95% confidence interval. BMI, body mass index; WHR, 
waist-to-hip ratio; HDL, high-density-lipoprotein; LDL, low-density-lipoprotein; HOMA-IR, 
Homeostasis model assessment of insulin resistance.
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Abdominal Gluteal Abdominal Gluteal
Pooled (n=17) 90.1±1.8 85.7±2.1 0.55±0.04 0.50±0.03
Caucasian (n=8) 88.6±2.5 89.1±2.1 0.49±0.04 0.53±0.03
African American (n=9) 91.4±2.6 82.7±3.3 0.59±0.06 0.47±0.04
Adipocyte Diameter (µm) Adipocyte Size (µg lipid/cell)
Table 4.2  Subcutaneous abdominal and gluteal adipocyte diameter size by race
Data are presented as mean±SE unless otherwise indicated.
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Figure 4.1.  Representative images of adipocytes isolated from subcutaneous adipose tissue 
samples of overweight-to-obese premenopausal women. (A) Caucasian abdominal, (B) 
Caucasian gluteal, (C) African American abdominal, and (D) African American gluteal.  100x 
magnification. 
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Figure 4.2.  Frequency distributions of adipocyte diameters from abdominal and gluteal 
subcutaneous adipose tissue (SAT) samples from premenopausal women.   (A) Average 
frequency histogram of adipocyte diameters in 10µm bins.  (B)  Relative frequency (in percent) 
of adipocytes in small (25-83µm), medium (84-142µm), and large (143-200µm) diameter 
subgroups in the abdominal and gluteal SAT.  Open bars represent abdominal region, shaded 
(grey) bars represent gluteal region.  Main effect of size p<0.0001.  † p<0.001 vs small and 
medium subgroups; n=17.  Data are mean ± SE.   
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Figure 4.3.  Racial differences in the frequency distribution of adipocyte diameters from (A) 
abdominal and (B) gluteal SAT samples of Caucasian and African American premenopausal 
women.  Open bars represent Caucasian group, shaded (black) bars represent African American 
group.  Diameter range 25µm-200µm; bins are 10µm.  n = 8 Caucasian; n = 9 African American. 
Data are frequency out of 250 cells mean ± SE.   
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Figure 4.4.  Relative frequency (in percent) of adipocytes in small (25-83µm), medium (84-
142µm), and large (143-200µm) diameter subgroups in the (A) abdominal and (B) gluteal SAT 
from Caucasian and African American premenopausal women.  (A) Size x race interaction 
p=0.064, main effect of size p<0.0001, race p=0.01.  (B) Size x race interaction p=0.03, main 
effect of size p<0.0001, race p=0.3622.  Open bars represent Caucasian group, shaded (black) 
bars represent African American group.  * p<0.05 vs Caucasian in same subgroup, † p<0.001 vs 
small and medium subgroups; n = 8 Caucasian, n = 9 African American.  Data are mean ± SE.   
  
 
 
CHAPTER 5:  Integrated Discussion 
 
 Effective regulation of adipose metabolism in the human body is a process that is 
essential for the maintenance of health.  The study of obesity has garnered great attention for the 
multitude of implications for chronic diseases risk as well as the status of obesity as a modifiable 
disease risk factor.  The mechanisms underlying regional adiposity at a most basic level are not 
completely understood.  One of the classic examples of region specific adiposity is the sex 
divergent body fat distribution of men and premenopausal women.  What makes this sex specific 
difference even more interesting is the shift from a preferential gynoid body fat distribution in 
premenopausal women to a more central body fat distribution after the menopausal transition 
(36).  This shift in regional adiposity is of particular importance because increasing central 
adiposity is highly associated with increased risk of cardiovascular disease, the Metabolic 
Syndrome, Type 2 diabetes, and even some types of cancer (1, 3, 4).  Although estrogen is 
implicated as a major player in determining body fat distribution, the mechanisms behind the 
estrogenic action(s) in adipose tissue of women are still unclear.  Discovery of estrogen receptors 
as well as estrogen producing enzymes such as aromatase and 17β-HSD in human adipose tissue 
supports the hypothesis that estrogen has direct actions within adipose tissue and that 
concentrations of circulating estrogens are not necessarily representative of estrogen action at the 
local level (114).   
The literature review in Chapter 1 suggests that one mechanism by which estrogen may 
influence adiposity in women is through effects on local lipolytic rate; the rate at which free fatty 
acids are mobilized from triacylglycerol storage in adipose tissue for fuel utilization in skeletal 
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muscle, liver and the heart.  However, results from previous investigations in animal models and 
humans conflict in regards to conclusions about the pro-lipolytic or anti-lipolytic nature of this 
effect, nor do they clearly demonstrate if estrogen’s influence occurs in a region specific manner 
to help maintain the preferential premenopausal gluteal-femoral body fat distribution.  The 
global aim of studies 1, 2, and 3 (discussed in Chapters 2, 3, and 4 respectively) was centered on 
determining how local estrogens influence regional lipolysis in overweight-to-obese 
premenopausal women and how characteristics, such as estrogen receptor content and adipocyte 
size, of abdominal and gluteal adipose tissue may influence regional lipid metabolism.  
Furthermore, we addressed whether the effects of estrogen and regional adipose tissue 
characteristics were different in well-matched subgroups of Caucasian and African American 
women.   
In study 1 (Chapter 2) we utilized the in situ microdialysis technique to determine the 
effect of increasing local subcutaneous adipose tissue estradiol concentrations on basal and 
stimulated/disinhibited lipolytic conditions in both the abdominal and gluteal regions of 
premenopausal women.  We found that estrogen perfusion influenced stimulated lipolytic rate 
(as indicated by glycerol release) in both pro- and anti-lipolytic manners depending upon the 
stimulatory/disinhibitory conditions and adipose tissue depot.  Estrogen served to blunt lipolytic 
stimulation by isoproterenol perfusion (β-adrenergic agonist) in the abdominal but not gluteal 
region.  Paradoxically estrogen enhanced lipolytic response to 30 minutes of submaximal cycle 
ergometry exercise during isoproterenol and phentolamine (α-AR antagonist) perfusion in the 
abdominal region, but blunted lipolytic response in the gluteal region under the same conditions.  
These results demonstrate a clear region and treatment dependent effect of estradiol on in vivo 
lipolysis, potentially influencing upper and lower adiposity in premenopausal women.  The 
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responses to estradiol perfusion were consistent between Caucasian and African American 
women, except for a tendency for racial differences in the effect of E2 on basal lipolysis.  These 
preliminary racial analyses indicate differential effects of estradiol on lipolysis may not be an 
underlying mechanism behind differences in body fat distribution in Caucasian and African 
American women, however further research needs to be conducted to confirm these results in a 
larger group of women. 
Study 2 (Chapter 3) focused on region specific expression of the three known estrogen 
receptors in adipose tissue, ERα, ERβ, and GPER.  Differences in abdominal and gluteal ER 
protein content were previously unknown.  We found that ERα and ERβ protein both differed 
between the abdominal and gluteal SAT.  GPER protein content, measured for the first time in 
human adipose tissue, was similar between the regions and between CA and AA women.  ERα 
protein was higher in abdominal compared to gluteal, and ERβ protein was higher in gluteal 
compared to abdominal in both CA and AA women.  ERα and ERβ have independent functions 
within adipose tissue, although knockout models have suggested that ERα confers the primary 
role of adiposity regulation (133, 135, 136), ERβ may repress or counteract the actions of ERα.  
Therefore, not only are the regional differences in the content of these receptors of significance, 
but also are the regional differences in the resultant ERα-to-ERβ ratio (127, 135).  We also found 
that waist-to-hip ratio is inversely related to gluteal ERβ protein content and positively related to 
the ERα-to-ERβ ratio in the gluteal region.  These data suggest it is possible that estrogen acting 
through ERβ (or decreased action through ERα) may be related to increased gluteal adiposity.  
This is the first evidence that there are regional differences in estrogen receptor protein content 
in SAT of women.  It is possible that this regional difference in ER content may be involved in 
estrogen’s region specific effects and potential modulation of regional adiposity, however, future 
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studies investigating ER signaling within abdominal and gluteal adipose tissue depots must be 
conducted before definitive conclusions can be drawn. 
In study 3 (Chapter 4) we utilized measurements of mean adipocyte size and adipocyte 
diameter distribution to preliminarily characterize regional and racial (CA and AA) differences 
in adipocyte morphology.  Although traditionally, according to association with disease risk 
factors, accumulating adiposity subcutaneously (in the abdominal, but more so, gluteal region) is 
considered preferable over increasing visceral adipose, this relationship is not apparent in obese 
AA women.  AA women accumulate less VAT/more SAT but have increased incidence of Type 
2 diabetes and hypertension compared to CA women for the same fat mass or BMI (23, 24).  
Both large and, more recently, small adipocytes have been implicated in contributing negatively 
to adipose tissue function and overall health (202, 203, 206, 238).  Our analysis of mean 
adipocyte size did not reveal a difference between the abdominal and gluteal region in the pooled 
population but did expose a tendency for divergence by race in adipocyte size by region; with 
AA adipocytes larger in the abdominal than gluteal region and CA adipocytes larger in the 
gluteal than abdominal region.  Adipocyte diameter distribution analyses broken down into 
tertiles allowed for a more detailed analysis of these racial differences.  We found CA women to 
have an increased proportion of medium sized adipocytes (84-142µm) in both the abdominal and 
gluteal regions in comparison to AA women.  On the other hand, AA women had an increased 
proportion of small adipocytes (25-83µm) in the gluteal region, and a trend for an increased 
proportion of large adipocytes in the abdominal region (143-200µm) compared to CA.  These 
results indicate a clear difference in adipocyte morphology in CA and AA women that may 
underlie the divergent race associated disease risk with SAT accumulation between these two 
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races, however investigations on larger groups of CA and AA women must be conducted to 
confirm these preliminary findings. 
In summary, the results of this project support the hypothesis that estrogen affects 
lipolysis through alterations in β-adrenergic stimulation as well as a potential non-adrenergically 
mediated mechanism, in a region specific manner.  Furthermore, abdominal and gluteal 
differences in ERα and ERβ protein could underlie region specific actions of estrogen, possibly 
playing a regulatory role in the preferential accumulation of adipose tissue in the gynoid SAT in 
premenopausal women.  Finally, morphologic differences in adipocyte size may be related to 
racial differences in disease risk associated with SAT adiposity in CA and AA women.  All three 
of these findings are integral to gaining a more complete understanding of the regulation and 
characteristics of upper and lower body SAT in premenopausal women.  
Although these results give further insight into the effects of estrogen within adipose 
tissue a significant amount of research is still necessary to clearly understand the multifaceted 
actions of estrogen within adipose tissue.  It will be important for future investigations to clearly 
delineate the mechanisms through which estrogen influences lipolysis in each specific adipose 
depot.  Although effects of estradiol on β-AR stimulation of lipolysis were confirmed here, 
actions through the α-AR receptors as well as potentially non-adrenergically mediated 
mechanisms such as ANP, insulin, adenosine, and cortisol (among others) must be considered 
and investigated thoroughly.  Examination of direct estrogen action on the post-receptor lipolytic 
signaling cascade is also needed to fully uncover the mechanisms through which estradiol may 
influence lipolysis.  In addition, determining the adipocyte sub-cellular distribution of ERα, ERβ, 
and GPER and the receptor specific signaling cascades that are initiated upon activation of these 
receptors by estrogen will help to connect regional differences in these receptors with tissue 
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specific effects of estrogen.  Finally, preliminary racial analyses presented here provide support 
for the importance of future studies investigating racial differences in adipocyte phenotype and 
biochemical processes which may underlie racial differences in prevalence of obesity and disease 
risk. 
The presence of estrogen converting enzymes as well as estrogen receptors within the 
adipose tissue of pre- and post-menopausal women leads to the hypothesis that there is a specific 
physiological purpose of the presence of estrogen within adipose tissue.  It is possible that the 
distinctive pre- and post-menopausal regional adiposity patterns occur for a specific evolutionary 
reason and that direct influence of estrogen within adipose tissue on lipid metabolism are 
necessary to maintain health throughout the lifespan.  Continuing investigations which will 
uncover the mechanisms underlying depot and pathway specific estrogen action within adipose 
tissue of both pre- and post-menopausal women is vital for our complete understanding of female 
health and regional adiposity related disease risk. 
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